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Abstract 
Heart valve disease is prevalent among Canadian population and worldwide; and for failing 
valves, the ultimate solution is valve replacement surgery. Bovine pericardial tissue is 
commonly used as a biomaterial to fabricate bioprosthetic heart valves (BHVs), however 
calcification of the soft tissue is an ongoing concern for its long-term performance. 
Calcification ultimately results in device failure due to regurgitation, stenosis, or both, which 
is caused by stiffening, tearing and rupturing of the tissue valve leaflets. This project 
investigates parameters related to bovine pericardial heart valve calcification. Three in vitro 
methods of calcium quantification in soft tissue were assessed using bovine pericardium (BP) 
– all three methods proved to be interchangeable with reliable results.  We investigated the 
use of dimethyl sulfoxide (DMSO) and sodium dodecyl sulfate (SDS) as mediums to 
effectively remove cell membrane phospholipid debris in efforts to inhibit or decrease 
calcification - calcium reduction of approximately 50% was achieved with the use of DMSO. 
Lastly, we microscopically examined fresh and glutaraldehyde (GA) treated BP to examine 
the inherent forms of calcium present – calcium sites associated with sulfur were discovered, 
which have not been reported in literature. These insights could lead to significant advances 
in BHVs. 
Keywords 
Heart valves, bioprosthetic heart valves, bovine pericardium, calcium, calcification, atomic 
absorption spectroscopy, inductively coupled plasma mass spectrometry, micro-computed 
tomography, dimethyl sulfoxide, sodium dodecyl sulfate, calcium sulfate, hydroxyapatite, 
ectopic calcification, soft tissue mineralization 
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Chapter 1  
1 Introduction 
This chapter will describe why heart valve research is important and necessary, followed 
by the objectives of this project. 
1.1 Background  
A significant population is affected by heart valve disease, ranging from children in more 
infrequent cases to the predominantly affected aging population (Schoen & Levy 2005; 
Simionescu 2004). Approximately 300,000 - 400,000 heart valve replacement surgeries 
are performed worldwide annually (Chambers 2014). There are two broad categories 
used to describe prosthetic heart valves: mechanical and bioprosthetic. Mechanical valves 
have superior durability, whereas bioprosthetic heart valves (BHVs) suffer from 
deterioration for a multitude of reasons. There is an increasing use of BHVs (Kulik et al. 
2006; Hoerstrup & Weber 2015), however over 50% of BHVs fail within 12-15 years 
(Siddiqui et al. 2009), demonstrating a need for substantial improvements. 
The function of heart valves is to allow unimpeded unidirectional blood flow throughout 
the four chambers of the heart during the cardiac cycle, and to prevent backflow. On 
average a human heart valve will experience over approximately 1 billion cardiac cycles 
over its lifetime (Balachandran et al. 2011), which emphasizes the importance of heart 
valve durability. The aortic valve specifically prevents retrograde flow into the left 
ventricle during diastole and allows blood to flow from the heart to the entire body. 
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(Misfeld & Sievers 2007) The implications are serious if the valve fails to open and close 
properly, as it can limit the ability of the heart to pump blood to the body’s organs 
sufficiently.  
Major heart valve diseases include: stenosis, which is the stiffening, thickening or 
narrowing of a valve or when the flaps of a valve fuse together; insufficiency, referring to 
regurgitation or back flow of blood through the valve; and less commonly, atresia, which 
is a condition where the valve opening does not develop at all, therefore lacking an 
opening for blood to pass through. (Rozeik et al. 2014) 
Heart valve diseases can be congenital or acquired later in life and can be comprised of 
one or more problem. The causes behind congenital heart diseases are challenging to 
identify, as they occur during the development of the heart before birth. Acquired heart 
valve disease can be caused by a number of factors including: age-related changes, 
rheumatic fever or infection (John & Liao 2006). Mineral deposition, most commonly 
calcium, is a process that normally presents itself on the aortic valve with age-related 
changes (Schoen & Levy 2005). Calcification of the aortic valve is one of the most 
common reasons that necessitates heart valve replacement; and although calcification is a 
well-known pathology, the mechanisms behind it are still largely unknown (Hopkins 
2005; Giachelli 1999). 
There are two main types of biomaterials that are currently used for the manufacturing of 
BHVs: porcine valves and bovine pericardium (Singhal et al. 2013). Since porcine valves 
are most similar in size to human valves, they can be explanted from pigs, chemically 
treated, and subsequently implanted into the patient in need. Bovine valves are too large 
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to exercise this procedure; therefore the pericardium (the sac that surrounds the heart) is 
alternatively used to fabricate valves of desired sizes. It is difficult to draw generalized 
direct comparison conclusions on the performance of porcine versus bovine valves due to 
the variation in valve manufacturers, patient populations and other limitations. However, 
bovine valves have exhibited superiority compared to porcine valves in incidents of 
complications and hemodynamic profile and are reported to be of better quality (Yap et 
al. 2013; Azarnoush et al. 2013).  
In order to sustain long-term durability and reduce antigenicity in the human body, 
bioprosthetic heart valves must undergo treatment(s) prior to implantation. The most 
common form of fixation is by chemically crosslinking the tissue with glutaraldehyde 
(GA) (Rémi et al. 2011; Chandran et al. 2011). GA has been the standard treatment 
method for heart valve tissue for over 50 years; it acts to suppress any immune host 
response and to stabilize the collagen in the tissue (Schoen & Levy 2005; Simionescu 
2004). Despite its extensive use, GA has also been shown to be a cause of calcification on 
the heart valve leaflets (Lee 2009; Weska et al. 2010), which ultimately results in device 
failure. This demonstrates a need for the modification of GA treatment of the tissue.  
There is a necessity for heart valve researchers to find novel treatment methods and 
advance with potential new heart valve models to improve the current situation 
surrounding BHVs; there must be progression in this direction in order to increase 
durability, reduce the rates of BHV failure and to expand the patient population that can 
be considered for BHV replacement surgery.  
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Overall this work focuses on bovine pericardial aortic valve replacements, investigating 
methods of calcium quantification in the soft tissue, potential anti-calcification treatments 
for BHVs, and the inherent properties of bovine pericardium. 
 
1.2 Objectives 
The overall objective of this thesis was to study calcification of bovine pericardium in 
relation to aortic heart valve replacements, ultimately working towards creating a valve 
with improved durability. 
The specific objectives of this research were: 
1. To develop a definitive method to assay calcium in soft tissue 
2. To assess the incorporation of a polar aprotic solvent (DMSO) treatment step into 
pericardial tissue processing for BHVs 
3. To assess the incorporation of an anionic surfactant (SDS) treatment step into 
pericardial tissue processing for BHVs 
4. To study the different forms of calcium present in fresh pericardial tissue and GA 
treated pericardial tissue 
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Chapter 2  
2 Literature Review 
This chapter will review and summarize literature that is relevant to calcification of 
bioprosthetic heart valves. The importance of native heart valve functions will be 
examined by reviewing the anatomy of the heart, followed by the diseases that heart 
valves may possess or acquire. In order to understand the tissue that is being replaced and 
the biomaterials that are used for their replacement, properties of native heart valve tissue 
and properties of the replacement tissue will be reviewed. Current replacement valves, 
their treatment procedures, and possible modes of failure will be examined in order to 
evaluate needs for improved durability of future bioprosthetic heart valves.  
2.1 Anatomy of the Heart and Blood Flow 
The heart is a vital organ that delivers oxygen-enriched blood throughout the entire body, 
allowing all other organs to work efficiently. The heart consists of two sides with four 
chambers; the left side is comprised of the left atria and the left ventricle, encompassing 
the aortic valve and mitral valve, while the right side consists of the right atria and right 
ventricle, consisting of the tricuspid valve and pulmonary valve (Figure 2.1). 
Deoxygenated blood that has circulated throughout the body enters the heart through the 
right atrium, passes through the tricuspid valve into the right ventricle and then is 
pumped through the pulmonary valve to the lungs. Once the blood is re-oxygenated in the 
lungs, it is directed to the left atrium, pumped through the mitral valve into the left 
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ventricle. The left ventricle then contracts, forcing the oxygenated blood through the 
aortic valve, initiating the cycle of systemic circulation to repeat. In a proper functioning 
heart, the four encompassed valves ensure unidirectional blood flow throughout 
circulation. (Whitaker 2014; Iaizzo 2009) 
 
Figure 2.1 Normal Human Heart Illustrating Position of Valves and Direction of 
Blood Flow  
(Stanford Children's Health 2015) 
2.1.1 Heart Valve Structure and Functions 
There are two types of heart valves present in the heart, atrioventricular and semi-lunar. 
The atrioventricular valves are situated between the right atrium and right ventricle 
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(tricuspid valve) and between the left atrium and left ventricle (mitral valve), whereas the 
semi-lunar valves lie between the right ventricle and pulmonary artery (pulmonary valve) 
and between the left ventricle and the aorta (aortic valve). (Iaizzo 2013) 
2.1.1.1 Atrioventricular Valves 
The two atrioventricular valves are the tricuspid valve, located on the right side of the 
heart between the right atrium and the right ventricle, and the mitral valve on the left side 
between the left atrium and the left ventricle. The tricuspid valve has three irregularly 
shaped flaps, while the mitral valve, also known as the bicuspid valve, has two irregularly 
shaped flaps. Both atrioventricular valves have the prominent support structure 
comprised of strong chordae tendineae and fibrous support cords. The chordae tendineae 
extend from the papillary muscles and myocardium on the ventricular wall to the middle 
layer of each flap. The function of the atrioventricular valves is to control blood flow 
from the atria into the ventricles. The chordae tendineae pull the valve leaflets together in 
order to prevent retrograde flow into the atria as the ventricle contracts. (Iaizzo 2009; 
Iaizzo 2013) 
2.1.1.2 Semi-lunar Valves 
The pulmonary and aortic valves possess three crescent shaped cusps, which respectively 
attach to the points where the pulmonary artery and the aorta leave the ventricles. They 
are less complex than the atrioventricular valves; they are also thinner and do not have 
chordae tendineae. The pulmonary valve regulates blood flow between the right ventricle 
and the pulmonary artery, and the aortic valve is the control between the left ventricle and 
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the aorta. Pressure increases as the ventricles contract, which passively pushes the valve 
leaflets upward, enabling blood to leave the ventricle. The leaflets are comprised of three 
distinctive layers: the ventricularis, spongiosa, and fibrosa. Details of the aortic valve 
composition are described below. (Iaizzo 2013; Rozeik et al. 2014) 
Composition of Aortic Valve Cusps  
The layer of the valve that faces the ventricle is called the ventricularis; it is composed of 
mainly elastin, aligned radially throughout the leaflet and some collagen. The elastin 
component allows for the endurance of high strain rates between cycles as the leaflets 
extend and also provides the necessary tension required to close the valve. The middle 
layer is known as the spongiosa, which is comprised mainly of glycosaminoglycans 
(GAGs) and loosely arranged collagen fibers that connect to the outer layers. The 
spongiosa functions to reduce tensile and compressive stress during the cardiac cycle due 
to its “jelly-like” nature, which permits internal shearing within the leaflet. The fibrosa is 
the layer that faces the aorta and it is made up of mostly collagen with a moderate amount 
of elastin. The collagen fibers in the fibrosa are circumferentially aligned, providing 
stiffness and strength to each leaflet. This arrangement maintains the arcs of the leaflets 
and also prevents back flow. The intricate network of these fibrous layers interacts to 
allow for proper valve functionality, and valvular interstitial cells (VICs) maintain this 
extracellular matrix (ECM). (Misfeld & Sievers 2007; Iaizzo 2013) Figure 2.2 illustrates 
the layers described above. The structure and composition of the native heart valve are 
important to study and take into account while considering potential materials for heart 
valve replacements. 
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Figure 2.2 Aortic Valve Leaflet Structure 
Adapted from (Wirrig & Yutzey 2014) 
2.2 Heart Valve Disease 
Any of the four heart valves can acquire disease from a number of physiological 
conditions; however the most commonly disease affected valve is the aortic valve and 
then the mitral valve (John & Liao 2006). Both valves are located on the left side of the 
heart where higher pressure loads are experienced, making them more prone to disease 
(Balachandran et al. 2011). The two most common forms of disease are stenosis and 
insufficiency. They will be discussed in further detail below. 
2.2.1 Aortic Stenosis 
Aortic stenosis is a common and serious form of heart valve disease. It occurs when the 
aortic valve opening is restricted, preventing proper blood flow from the left ventricle to 
the aorta and subsequently to the rest of the body (Dweck et al. 2012). Aortic stenosis is 
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initiated when there is an imbalanced distribution of mechanical stress on the valve; this 
triggers damage to the endothelium and allows for lipid infiltration, which further 
instigates inflammatory response signalling. With the contribution of signalling 
molecules and cells, this pathway eventually advances to fibrosis and calcification, 
restricting the valve (Rayner et al. 2014). This results in increased pressure to the left 
ventricle during the cardiac cycle. In order to compensate for the restricted opening, the 
left ventricle enlarges (hypertrophy), but this temporary solution only exacerbates the 
malfunctioning of the whole heart due to the continued increasing demand on the heart’s 
components (Martin 2013).  
2.2.2 Aortic Insufficiency 
Aortic insufficiency, also known as regurgitation, occurs when the aortic valve allows 
back flow from the aorta into the left ventricle. An abnormal structure of the valve or 
weakening of the valve leaflets can cause this, and in the case of acute aortic 
regurgitation it can also be caused by infection, injury or high blood pressure. Any of 
these occurrences will prevent a full seal of the valve. Similar to the process that occurs 
in aortic stenosis, the heart tries to compensate for the lack of blood flow via an increase 
in ventricle size to retain the required output, which initiates the same detrimental 
pathway that eventually leads to failure if left untreated. (Rozeik et al. 2014; John & Liao 
2006) 
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2.3 Prosthetic Heart Valves 
Prosthetic heart valves provide an alternative for diseased valves, offering the patients a 
chance at survival. Although this is not an indefinite cure, valve replacement is often the 
patient’s last treatment option and at least improves their life expectancy and symptoms. 
Ideally, a valve replacement would mimic the features of our native valve as closely as 
possible. If the perfect heart valve replacement existed, it would have a high resistance to 
thrombosis, superior hemodynamics, it would be easy to implant and would have an 
indefinite lifetime. Regrettably, to date no such valve exists (Pibarot & Dumesnil 2009). 
Surrounding the time that prosthetic heart valves emerged there were progressions made 
that had a significant effect on their clinical outcome. Unfortunately the efforts that have 
been made in the last few decades have been producing minimal improvements (Zilla et 
al. 2008). There are two broad categories for current heart valve replacements: 
mechanical and bioprosthetic. Mechanical valves are manufactured from man-made 
materials such as metal (titanium, stainless steel) or ceramics. These valves are very 
durable and have a long lifetime, however they also require a lifelong administration of 
anticoagulants since thrombogenecity is of high risk (Schoen & Levy 2005; Pibarot & 
Dumesnil 2009). Bioprosthetic valves are constructed from biological tissue, namely 
human tissue (if available), porcine valves, or bovine pericardium; and though they are 
more similar in nature to and can resemble more closely our native heart valve than 
mechanical valves, their largest disadvantage is poor durability (Simionescu 2004; 
Vesely 2003). Both types of valves have their benefits and drawbacks, however every 
case is different and must be assessed individually to determine what type of valve best 
fits the criteria for the specific patient. There is also ongoing research surrounding the 
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development of tissue engineered heart valves and though there may seem to be 
promising results, there is still a long way to go before tissue-engineered valves become 
common practice. Figure 2.3 depicts different types of available prosthetic valves, 
ranging from mechanical to bioprosthetic. 
 
Figure 2.3 Different Types of Prosthetic Valves:  
A, Bileaflet mechanical valve (St Jude); B, Monoleaflet mechanical valve (Medtronic 
Hall); C, Caged ball valve (Starr-Edwards); D, Stented porcine bioprosthesis (Medtronic 
Mosaic); E, Stented pericardial bioprosthesis (Carpentier-Edwards Magna); F, Stentless 
porcine bioprosthesis (Medtronic Freestyle); G, Percutaneous bioprosthesis expanded 
over a balloon (Edwards Sapien); H, Self-expandable percutaneous bioprosthesis 
(CoreValve) (Pibarot & Dumesnil 2009) 
2.3.1 Mechanical Valves 
The three main types of mechanical valves are shown in Figure 2.3 (A, B, C). The first 
edition of mechanical valves was the ball valve, which was first successfully implanted 
by Charles Hufnagel in 1952 by placing the valve heterotopically in the descending aorta 
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(Kwasny et al. 2013). Albert Starr was first to place the ball valve in the mitral position in 
1960. The ball valve that was designed by Starr and M. Lowell Edwards underwent 
several modifications in an effort to reduce its thrombogenecity, however anticoagulation 
therapy was a need that continued for patients (Chaikof 2007). Disc valves emerged, 
which have monoleaflet (single disk, Figure 2.3, B) and bileaflet (2 semilunar disks, 
Figure 2.3, A) designs. When the tilting disk was first introduced in the late 1960’s, it 
was a step forward since the resistance to forward flow was minimized in comparison, 
there was a decrease in turbulence, it limited regions of stagnation and reduced shear 
stress. This design reduced anticoagulation therapy requirements, however it did not 
completely eliminate the need. The bileaflet valve emerged in 1977, with the idea of 
having unimpeded central flow. The use of thromboresistant alloys and advanced 
ceramics was beneficial and the valve possessed superior hemodynamics in comparison 
to its predecessors, however the need for anticoagulation therapy still remained (Chaikof 
2007). In general, mechanical valves are known for their superior structural integrity and 
high durability, however the obstruction of blood flow by the leaflets poses a significant 
problem. Firstly, the physical presence of an occlusion presents blood flow abnormalities 
and secondly, the blood contacting material being non-physiologic poses a compatibility 
issue. The obstruction causes inconsistency of stress through the valve, which results in 
cell rupture and thrombosis. In order to counteract the risk of thrombosis, the use of anti-
coagulants is necessary. The side effects of this therapy come with their own risks, 
including fatal hemorrhagic incidents. As with any manufactured device there also lies a 
risk of faulty design and/or construction, which can lead to the failure of the device. 
(Simionescu 2004; Siddiqui et al. 2009) 
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2.3.2 Bioprosthetic Valves 
Bioprosthetic valves are either fully or at least partially composed of biological tissue. 
There are three main sources of bioprosthetic valve tissue: human, porcine (pig origin), 
and bovine (cow origin). Human tissue valves would undoubtedly be most suitable and 
desirable, however the availability of human valves is low. When obtainable, human 
tissue can either be harvested from the same patient (autograft), or it can be from another 
human (homograft). Donald Ross implanted the first allograft aortic valve in the 
subcoronary position in 1962 (Hoerstrup & Weber 2015). It was at this time that the 
biological and hemodynamic advantages of using cadaveric heart valves became apparent 
(Chaikof 2007). As previously mentioned, these valves are limited in supply, therefore it 
was necessary to look at other tissue sources as a substitute material. Another approach 
that is used with human tissue valves is known as the Ross procedure, which entails 
moving the patient’s pulmonary valve to replace the aortic valve and replacing the 
pulmonary valve with another homograft. The rationale behind this procedure stems from 
the pressure differential between the right and left side of the heart. The right side, where 
the pulmonary valve lies, withstands approximately 1/5 of the pressure that the left side 
experiences. Therefore by placing the patient’s own living valve in the high-pressure 
region, it holds better promise for long-term durability. (John & Liao 2006; Chambers 
2014) 
The first experience with heterografts/xenografts was in 1965 by Jean-Paul Binet and 
Alain Carpentier. They had 5 patients that had undergone heart valve replacements with 
heterografts and all survived (Ratner et al. 2013). Although promising, these valves 
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suffered from deterioration. Carpentier continued to work on advancing the technology 
and eventually found that GA was superiorly effective in increasing the tissue stability 
and decreasing immunoreactivity in comparison to other tested compounds (Acton 2013). 
In 1968 Carpentier implanted the first successful GA treated xenografts and the first 
commercialized valves were introduced in 1970 (Carpentier Edwards porcine aortic 
valve) and in 1972 (Hancock). The modifications made since that time include improving 
design flaws, such as misplaced suspension stitches, efforts to reduce the valve profile, 
and the addition of anti-calcification treatments. (Zilla et al. 2008) 
Due to farming of animals, xenograft material is abundant in comparison to human tissue. 
The two main types of xenografts that are currently used, porcine valves and bovine 
pericardial valves, are different in nature. Porcine replacement valves are made from the 
porcine heart valve tissue itself, whereas the bovine tissue that is used to fabricate valves 
comes from the pericardium (sac that surrounds the heart). Both porcine valves and 
pericardial valves can be stented (mounted on a metallic/polymeric support stent) or 
stentless (no external support stent). Stentless valves were developed in efforts to 
improve biocompatibility and the long-term durability of tissue valves by reducing non-
physiological materials. Unfortunately they have not been as successful as hoped or 
predicted (Chambers 2014; Zilla et al. 2008). 
The use of these soft tissues allows for the valve design to be substantially more similar 
to our native heart valve, alleviating some of the problems that arise from mechanical 
valves. Thrombogenecity becomes less of a concern due to superior biocompatibility and 
the semi-lunar design allows for the conventional stream of blood flow (Chandran et al. 
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2011). These improvements also render anticoagulation therapy unnecessary, which is a 
great benefit to a significant portion of the patient population. 
Although bioprosthetic valves may seem desirable for a number of cases as opposed to 
mechanical valves, they do pose some challenges of their own - their most tragic 
shortcoming being their limited lifespan, ranging only from approximately 10-15 years 
(Iaizzo 2013). The principal cause for bioprosthetic heart valve failure is structural 
deterioration, either from calcification or non-calcific incidences such as cusp tearing as a 
result of collagen degradation and lack of repair mechanisms (Schoen & Levy 2005; 
Simionescu 2004). In order to suppress the body’s immune response to foreign tissue, 
bioprosthetic valves must be treated prior to implantation. The standard treatment uses 
GA crosslinking as a fixative, blocking immune responsive sites and stabilizing the 
tissue. Although this treatment is necessary, it also has been shown to contribute to 
calcification of the valve, leading to failure (Lee 2009; Manji et al. 2014). Valve design is 
also an important factor to consider in non-calcific deterioration occurrences. Since most 
tissue valves are stented, there are regions that are subjected to increased stress, for 
example where the sutures lie. Repetitive abrasion between the fabric and pericardium 
could result in tissue damage (Siddiqui et al. 2009; Butany et al. 2011). Other 
complications can also arise with bioprosthetic heart valves such as infection, namely 
infective endocarditis, causing inflammation and subsequent degeneration (Singhal et al. 
2013; Butany et al. 2011). Since calcification is a large focus of this thesis, it will be 
discussed in further detail later in this chapter (sections 2.6, 2.7). This work also focuses 
on bovine pericardium as a biomaterial for BHV fabrication and will be emphasized 
accordingly from here on in. 
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2.4 Pericardium as a Heart Valve Replacement Material 
Pericardium is the tissue sac that surrounds the heart. It is a widely used biomaterial for a 
number of bioprostheses, including and most commonly for heart valves (Iaizzo 2009; 
Rémi et al. 2011). The pericardium serves multiple purposes, including but not limited to: 
prevention of adhesion to surrounding tissues, providing a natural barrier to the heart, 
maintaining the heart’s anatomical position, and preventing over dilation of the heart 
(Whitaker 2014). As a heart valve substitute material, pericardium offers the benefit of 
providing sheets of material to fabricate valves of multiple sizes with, which may make it 
easier to handle for manufacturing compared to porcine valve tissue. The mechanical 
behaviour of pericardial tissue under stress is determined by its structure and 
composition. 
2.4.1 Structure and Composition 
The pericardium consists of two layers: the fibrous pericardium, which is the outermost 
layer and the serous pericardium, the inner layer, which is in fact a sac itself. The layer of 
the serous pericardium that surfaces the heart is known as the visceral layer and is also 
the heart’s epicardium; the side that neighbours (and is attached to) the fibrous 
pericardium is called the parietal layer. Between the fibrous and serous pericardium is a 
region known as the pericardial cavity, which contains a lubricating fluid. The layers of 
the pericardium are illustrated in Figure 2.4. The pericardium is essentially connective 
tissue lined with mesothelial cells and is composed primarily of collagen (approximately 
90%, predominantly type I), some elastin (<5%), glycoproteins, and GAGs. The portion 
of the pericardium that is removable is the parietal layer with the fibrous pericardium - 
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this provides a two-layered structure for biomaterials applications. The dynamic nature of 
pericardium allows it to alter itself according to its environment and mechanical loading 
under physiological conditions. This contributes to the variation of tissue properties 
within the sac, including the thickness of the material, fiber alignment, and thus 
mechanical properties. (Rémi et al. 2011; Iaizzo 2009; Whitaker 2014) 
 
Figure 2.4 Pericardium Location and Structure  
(Vegas 2012) © 2012 Springer Science+Business Media, LLC. Used by Permission. 
2.5 Tissue Mechanical Properties  
An important aspect of using biological tissues as biomaterials in the human body is 
having an understanding how they respond to forces that they will endure under 
physiological conditions. These biomechanics characterize the performance and 
durability of a material. Studying mechanical properties of tissues is normally done in a 
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well-controlled environment using a geometrically simple material sample; a defined load 
is applied and the tissue response is measured. In order to understand the application of 
biomechanical property testing to heart valve tissue, this section describes some 
important terms and concepts relevant to the aortic valve. 
2.5.1 Loading 
Loading is referred to the application of a force to an object. There are several different 
types of loading, such as: tension, compression, shear, and bending. In tension loading, 
both ends of a material are pulled in opposite directions (elongated). Compression testing 
involves the exact opposite of this, basically squeezing a material. Bending essentially 
consists of both tension and compression, as it applies a load that arcs a material, causing 
one side to be stretched and the other side to be compressed. Shear loading occurs when 
the force applied is parallel to the plane of a material. This force causes layers or parts 
within a material to slide in opposite directions. How these four loading conditions apply 
to the aortic valve will be explained in further detail below. (Jia 2014; Ratner et al. 2013) 
2.5.2 Stress - Strain 
The term stress refers to the loading of an applied force to a specific cross-sectional area 
of an object, while strain refers to the response of a system to an applied stress 
(Javidinejad 2015).  
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2.5.2.1 Tensile and Compressive Stress – Strain 
During diastole the aortic valve experiences tensile stretching, and the pressure felt by the 
aortic valve also puts a compressive stress on the valve leaflets. The valves are 
simultaneously being stretched as the valve closes, and the aortic surface (fibrosa) of the 
valve is subjected to pressure, causing internal compression. The abundance of collagen 
fibers in the fibrosa provides the strength required to withstand the stretching. 
(Balachandran et al. 2011). 
The modulus of elasticity (E), also known as they Young’s modulus, is a measure of the 
stiffness of a material. This can be measured using the stress and strain values using the 
following equation: 
E= stress/strain      (2.1) 
2.5.2.2 Shear Stress – Strain 
An example of shear stress and resulting deformation is shown in Figure 2.5. Shear stress 
is also the force divided by the area over which it acts. Shear strain is the result of the 
relative displacement of the surfaces divided by the thickness of the material. An 
important parameter related to shear stress-strain is the shear modulus or modulus of 
rigidity, denoted by G; G is the ratio of change in shear stress over the change in shear 
strain.  
Shear stress – strain is pertinent to the aortic heart valve, as during systole the ventricular 
surface of the leaflets is subjected to shear stress as the blood flows past the leaflets. 
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There is also shear stress on the aortic surface of the valve during diastole as blood 
accumulates in the sinuses (Balachandran et al. 2011).  
 
Figure 2.5 Schematic of Tensile, Compressive and Shear Forces 
2.5.2.3 Bending 
Bending is a reoccurring motion for heart valves as they open and close. As the curvature 
of the leaflets change, the valve is subjected to bending stress. If the stiffness of the 
leaflet increases, as is the case with some diseased valves (both native and replacement 
valves), the bending stress also increases, which can contribute to early failure of the 
valve. Sharp bending produces large amounts of stress on the valve leaflets that can lead 
to mechanical fatigue and local structural collapse, a phenomenon known as buckling. In 
comparison to other mechanical testing methods, bending is difficult to measure 
uniaxially in heart valve leaflets. This is due to the material properties, as the tissue is not 
a rigid material and instead is quite pliable. Biaxial testing and three point bending 
techniques have been used alternatively. (Shah & Vyavahare 2008)  
An illustration of the mechanical forces that the aortic valve experiences is shown below 
in Figure 2.6. 
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Figure 2.6 Schematic of Mechanical Forces on Aortic Valve during Peak Systole and 
Peak Diastole  
(Balachandran et al. 2011) 
2.5.2.4 Anisotropy 
If a material exhibits properties of varying mechanical properties when measured in 
different directions, it is known as an anisotropic material. Since the properties of these 
materials are determined and are dependent on the direction in which they are measured, 
anisotropic materials are more difficult to describe than isotropic (not directionally 
dependent) materials (Ratner et al. 2013). Both native heart valve tissue and bovine 
pericardial tissue are anisotropic materials (Zioupos & Barbenel 1994; Chandran et al. 
2011; Zioupos et al. 1994).  
2.5.2.5 Viscoelasticity 
Viscoelasticity refers to the property of a material that demonstrates conjoint 
characteristics of a viscous (fluid) material and an elastic (solid) material. The rate of 
stress or strain that is inflicted on the material dictates the relationship of stress and strain, 
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indicating a time dependency. This can also be seen in the occurrence of creep, when 
strain continues to change in the direction of deformation while being held at a given 
stress. A common method used to characterize viscoelastic behaviour is by stressing the 
material cyclically (sinusoidally), exposing a phase lag between the stress applied and 
resultant strain. The unloading curve is also lower than that of the loading curve in 
viscoelastic materials, demonstrating an energy loss. Most biological tissues, including 
heart valve tissue, exhibit viscoelastic behaviour. (Findley et al. 1976) 
2.5.3 Pericardium Mechanical Testing and Properties  
Several studies have been conducted to evaluate the mechanical properties of heart valve 
tissue, including human tissue, porcine tissue, and bovine pericardial tissue. These types 
of experiments are necessary in order to determine the native tissue characteristics as well 
as to assess the suitability and safety of these biomaterials. A review of some of these 
tests and their findings will be summarized below, focusing on pericardium.  
Uniaxial tensile testing is a relatively easy method used to characterize tissue. Basically, 
a strip of material is clamped at both ends and stretched to a defined load. The load and 
the tissue extension response is recorded, which can then be converted into stress and 
strain. With known values of tensile stresses under physiological conditions, these tests 
are useful in determining whether a material will be able to maintain their stability in a 
given environment. Stress – strain curves obtained from tensile testing has shown non-
linear behaviour of pericardium (Balachandran et al. 2011; Mavrilas et al. 2005; 
Thubrikar et al. 1983). 
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Unidirectional strain is not an accurate depiction of what is experienced by a heart valve, 
thus there is some criticism of uniaxial tensile testing. Biaxial testing employs the use of 
a square piece of tissue that is clamped at the edges and can be loaded either on one side 
or both. By analyzing the deformation of markers on the surface of the sample, the 
change in deformation can be assessed (Billiar & Sacks 2000; Zhu & Barthelat 2011). 
Pericardium is a good candidate for biaxial testing, since larger sample areas are more 
easily acquired as compared to (human or porcine) valve leaflets. Biaxial testing has been 
shown to simulate physiological conditions more accurately than uniaxial (Paez & Jorge-
Herrero 1999). Furthermore, multiaxial testing is another option that can subject a 
multitude of forces to a material simultaneously (Sacks & Sun 2003; Arcidiacono et al. 
2005).  
Additionally, the conditions and parameters used in tensile testing have been shown to be 
of importance. For example, Lee et al. (1994) demonstrated using both small and large 
deformations that higher strain rates for testing offered a better evaluation of viscoelastic 
properties (Lee, J.M 1994). Cyclical loading also provides insight to tissue fatigue 
properties (Wells et al. 2005).  
Shear testing has also provided insight into the material properties of bovine pericardium. 
Boughner et al. (2000) studied the change in shear properties of pericardium after GA 
treatment. They found that at low shear stresses, GA fixed pericardium had a high 
resistance to shear that fresh pericardium did not exhibit. This could be attributed to the 
disruption of collagen fibers that occurs during GA fixation. The shear properties of 
pericardium are important to consider for bioprosthetic valve use, since in order for the 
valve leaflet to bend smoothly internal shearing must take place.  
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Alternatively, Mirnajafi et al. (2005) have studied flexural properties of pericardium by 
means of a three-point bending technique and compared results between fresh and fixed 
tissue. The findings suggest that the flexural properties of bovine pericardium are largely 
attributed to the inter-fiber crosslinks, rather than the actual collagen fiber stiffness 
(Mirnajafi et al. 2005). 
Overall, a range of mechanical testing studies have given insight into the material 
properties of pericardium, revealing it’s non-linear, anisotropic, and viscoelastic nature.  
2.6 Chemical Crosslinking  
As stated previously, it is essential to crosslink bovine pericardium before implantation 
into patients in order to stabilize the tissue. Although GA is the most frequently used and 
standard agent for BHVs, there are additional methods that have been researched and 
used, such as carbodiimides, genipin, epoxides, acyl azides and photo-oxidative 
crosslinking (Vasudev, S.C. et al. 1997; Jorge-Herrero, E. et al. 1999; Bernacca et al. 
1992; Vyavahare, N. et al. 1997). Since GA is the ‘gold standard’ for use in BHVs, it will 
be discussed in further detail below. 
2.6.1 Glutaraldehyde 
GA (pentane-1,5-dial, C5H8O2) is an organic compound that is commonly used as a 
crosslinking agent for a variety of applications, including the fixation of BHVs. GA can 
form several possible structures in aqueous solution (Figure 2.7), making its crosslinking 
mechanisms difficult to explain. Thus, over the years, several hypotheses have been put 
forward in attempt to explain GA crosslinking in aqueous solution. For proteins 
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specifically, there have also been several postulations as to how they crosslink with GA, 
and the mechanism is yet still poorly understood (Migneault et al. 2004). In general, the 
amino groups of proteins are implicated in the reaction, as their nucleophilic nature 
renders them highly reactive (Jayakrishnan & Jameela 1996; Hopkins 2005; Cheung et al. 
1990). Figure 2.8 illustrates the possible reactions of proteins with GA in aqueous 
solution. 
Within the structure of pericardium, collagen offers the amine functionality required for 
crosslinking and involves the amino acid residues lysine and/or hydroxylysine. 
Seemingly, a mechanism that is commonly noted for the crosslinking of collagen-
containing tissue is the formation of a Schiff base by the aldehydes upon the exposure to 
the amino groups. However, considering that GA can exist in various aqueous forms, it is 
reasonably plausible that more than one reaction mechanism could be simultaneously 
contributing to the crosslinking (Migneault et al. 2004). 
 
Figure 2.7 Possible Forms of GA in Aqueous Solution 
(Migneault et al. 2004) © 2009 BioTechniques. Used by Permission. 
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Figure 2.8 Possible Reactions of GA with Proteins  
(Migneault et al. 2004) © 2009 BioTechniques. Used by Permission. 
GA is used as a crosslinking agent in biological tissues to stabilize the material by the 
crosslinking of collagen, a reduction in antigenicity, and prevention of enzymatic tissue 
digestion. It is has also been shown to aid in sterilization (Golomb et al. 1987; Schoen & 
Levy 2005). The effectiveness of GA crosslinking in tissue is dependent on certain 
parameters, such as: the concentration of GA, the purity of GA, the time of tissue 
exposure to GA, and the temperature and pH of reaction (Vyavahare, PhD et al. 1997; 
Cheung et al. 1990). Low concentrations of GA are effective in keeping the stiffness of 
the tissue at an appropriate level, however the extent of sterilization and stabilization is 
reduced. Higher concentrations produce the opposite results. High-temperature fixation 
has been shown to allow for lower concentrations of GA, due to increased crosslinking 
and higher diffusion rates. More uniformity of crosslinking was also demonstrated with 
higher temperatures (Jayakrishnan & Jameela 1996). The effect of pressure during 
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fixation has also shown to be of consideration. Collagen organization within the tissue 
appeared to be compressed when high-pressure fixation was employed, while low-
pressure fixed samples resembled more similar to native valve morphology (Hopkins 
2005). The significance of pressurized fixation is not definite, however the supposition is 
that retaining native aortic morphology (as much as possible) assists in the ability of the 
heterologous material to endure the mechanical forces that it is subjected to in the heart. 
All of the abovementioned fixation parameters could contribute to the long-term 
durability of heart valve bioprostheses. 
Although tissue crosslinking with GA is necessary and has its benefits, it does not come 
without consequences. GA fixation has been shown to cause inflammatory response and 
is known for its cytotoxicity, exposing the tissue to infection and inhibiting tissue 
remodeling (Giachelli 1999; Kim et al. 1999). Beyond the point of stability, the increase 
in tissue stiffness is also undesirable and in some cases induces tissue buckling. 
Conventional GA fixation induces calcification, which ultimately leads to failure of the 
valve (Manji et al. 2014; Cunanan et al. 2001). This has been attributed to residual 
cytotoxic GA and cell debris remaining in the tissue post-fixation, which can lead to toxic 
effects and biomineralization. Since calcification is a major effect and challenge of GA 
crosslinking and is also a large focus of this thesis, it will be discussed further in the next 
section. 
2.7 Ectopic and Dystrophic Calcification 
Inappropriate biomineralization occurring in soft tissues is known as ectopic calcification 
(Giachelli 1999), whereas calcification that occurs in degenerated or necrotic tissue is 
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referred to as dystrophic calcification (Bonucci 2007; Li & Uitto 2013). Native heart 
valve calcification is always ectopic and is sometimes dystrophic; it does occur that 
valvular calcification develops in inflamed or damaged tissue, implying dystrophic 
calcification, but it is not always the case. Conversely, bioprosthetic heart valve 
calcification is almost always termed dystrophic, as deposition of the valve itself is 
inflicting damage to the local area. The following section will discuss ectopic and 
dystrophic calcification of soft tissues, with an emphasis on heart valve tissue. 
2.7.1 Calcification of Heart Valve Leaflets 
When ectopic calcification occurs on vital organs such as heart valves, the consequences 
are severe and can be fatal. There are a number of possible mechanisms that attempt to 
explain heart valve calcification, since any one precise mechanism is unknown; and there 
is also evidence that multiple mechanisms may simultaneously contribute to the 
occurrence of calcification. Factors influencing calcification of natural and bioprosthetic 
heart valves are explored below. 
2.7.1.1 Regulatory Mechanisms of Calcification 
Previously, calcification of heart valves was believed to be a passive, degenerative 
process; however more recently, studies have shown evidence that it is an active, cell-
mediated process that involves a vast range of molecules (Stones 2007; Ronchetti et al. 
2013). Several regulatory mechanisms have been proposed in literature, most of which 
implicate osteopontin (OPN). OPN is an acidic phosphoprotein that is found in 
mineralized tissues such as teeth and bone; and in such hard tissues, OPN regulates the 
rate of bone formation and bone resorption via osteoblasts and osteoclasts respectively 
32 
 
(Sodek et al. 1994). Although OPN is not as extensively expressed in soft tissues, studies 
have reported OPN richness in ectopically calcified sites (Rajachar et al. 2009). A 
number of research groups have now implied OPN as an ectopic calcification inhibitor 
(Kazama et al. 2006; Lee 2009).  
In 2002, Steitz et al. suggested that in addition to inhibiting mineral deposition, OPN 
promotes regression of calcification via carbonic anhydrase II (CAII), which induces 
acidification of the local environment and dissolution of residual bioapatite. Reverting 
mechanisms were enhanced due to OPN’s ability to recruit and migrate additional 
macrophages, and it was also speculated that bone resorption was facilitated by CAII 
regulation (Steitz et al. 2002). Ohri et al. (2005) also investigated OPN as an inhibitor of 
ectopic calcification and drew similar conclusions, indicating CAII expression was 
important in the mechanism of action (Ohri et al. 2005). In 2009, Rajachar et al. also 
tested this hypothesis using a CAII knockout method. The conclusions were consistent in 
both manners and demonstrated mitigation of calcification with OPN, and also showed 
that the mitigation was dependent on CAII, since inhibition was not achieved by OPN 
expression alone. (Rajachar et al. 2009) 
Angiogenesis has also been associated with ectopic calcification. The theory behind the 
link is that the new blood vessels can act as a conduit for osteoprogenitor cells. 
Endothelial cells releasing cytokines can induce the differentiation of osteoprogenitor 
cells, and with the provision of an encouraging environment, it is rather plausible that an 
osteogenic pathway could ensue. This association attempts to provide a cellular link 
between angiogenesis and ectopic calcification, as there is evidence that the 
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osteoprogenitor cells produced by the cytokines are the pericytes that exist in the new 
blood vessels. (Collett & Canfield 2005) 
Other studies have proposed mechanisms involving collagen remodeling of the fibrosa 
layer of heart valve leaflets. Aortic disease has been shown to increase the collagen 
remodeling, however this fibrosis and calcification correlation is still poorly understood 
(Wirrig & Yutzey 2014).  
Although there are similarities between ectopic calcification of various soft tissues, there 
seem to be underlying differences on a molecular level, for example even between 
valvular calcification and vascular calcification, as the cell types involved are expected to 
be different. This shows that while efforts are being made to inhibit ectopic calcification 
of soft tissues in general, successful therapies will need to account for unique regulatory 
mechanisms and cellular influences that are tissue specific. (Wirrig & Yutzey 2011)  
Overall, mouse knockout models and evidence of gene expression from bone cells have 
lent to a new definition and understanding of ectopic calcification on a molecular level, 
indicating that it is an active and regulated process; and although there has been 
significant progress in identification of potential regulatory pathways and mechanisms, 
much remains to be revealed about specific functionality and utility for disease 
comprehension and treatment.  
2.7.1.2 Effects of Glutaraldehyde Crosslinking on Calcification 
As mentioned earlier, the benefits of GA crosslinking come with consequence - a major 
drawback being the initiation of calcium deposition.  The calcium influx theory has been 
a frequently proposed mechanism of action by GA to induce calcification, where an 
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increase in calcium concentration being exposed to high phosphate levels causes 
precipitation of calcium phosphate minerals (Giachelli 1999). GA toxicity is also 
problematic and may lead to dystrophic calcification by leaching out of BHVs, causing 
damage to surrounding tissue (Stones 2007). It has been demonstrated that there is indeed 
a quantitative relationship between the amount of GA and calcium deposits (Lee 2009). 
Crosslinking renders the tissue cells nonviable, imparting a loss of regulatory action from 
cells; and as mentioned above, regulatory mechanisms could be substantially involved in 
calcification. 
2.7.1.3 Effects of Mechanical Stress on Calcification 
Heart valves are subjected to repetitive mechanical stress as they open and close. This has 
been suggested to intensify calcification in BHVs, as high degrees of mineralization have 
been shown to correlate to areas of high mechanical stress (Thubrikar 1983). Tensile 
stresses during diastole were initially hypothesized to inflict cuspal tearing, however 
further studies revealed that flexural fatigue is associated with tissue rupture (Vesely 
2003). Stress has also been implicated in BHV calcification and subsequent failure since 
studies have found higher rates of failure in the left side of the heart, where there are 
higher pressures and stresses inflicted on the valves versus the less stressed right side 
(Simionescu 2004). The cyclic compressive stress on the valve leaflets has also been 
linked to the disruption of collagen architecture, inducing calcification by exposing 
calcium-binding sites (Vesely 2003). 
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2.7.1.4 Host Factors that Affect Calcification 
It is known that there are inherent host factors that affect the success or failure of heart 
valve replacements. Age is of high concern in that regard, as children and adolescents 
have the highest rate of early primary tissue failure. The risk is substantially increased for 
patients <35 years old, as failure occurs within 5 years in almost every case of a patient 
younger than 35, whereas approximately only 10% fail in patients >65 years of age. 
Although the reasoning behind this factor is not completely understood, it can be 
attributed to superior immune system proficiency of younger individuals (Siddiqui et al. 
2009) and/or higher rates of metabolism (Simionescu 2004).  
Other host factors that can affect valve replacements are congenital anomalies or if the 
patient has another condition that can cause inflammatory responses, such as renal 
disease and rheumatic fever. Genetic factors can also play a role in soft tissue 
calcification (Goldbarg et al. 2007). 
2.7.1.5 The Role of the Organic Matrix of Heart Valve Tissue on 
Calcification 
As can be seen from the abovementioned points, different constituents of heart valve 
tissue (collagen, elastin, VICs) have all been implicated in the origin of calcification. The 
breakdown of collagen has been associated with the initiation of calcification in a number 
of studies, ranging from the effect of mechanical stress to an effect of macrophage 
deposition on the valve (Siddiqui et al. 2009). Elastin has also been implicated in earlier 
years as an origin for calcification and has been shown to calcify (Stones 2007). The role 
of elastin in calcification is still a point of interest (Perrotta et al. 2011). Conversely, cells 
control the molecular regulatory mechanisms in the valve tissue and there is an increasing 
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emphasis being placed on these pathways; as they are implicated in differentiating into 
osteoblast-like cells, contributing to calcification (Sage et al. 2010; Duer et al. 2008); 
furthermore, GA treatment renders the tissue cells unable to regulate and function 
normally, which has also been shown to lead to calcification (Schoen & Levy 2005). 
Overall, although many studies have been performed in efforts to understand the source 
of calcification of native and bioprosthetic heart valves, much remains undetermined and 
no single mechanism can explain the occurrence. Considering all of the potential 
mechanisms, it is indeed conceivable that multiple mechanisms work concurrently in the 
event of calcification. Further studies must be conducted to assist in understanding these 
mechanisms, enabling the use of knowledge to prevent and/or treat disease. 
2.8 Anti-Calcification Strategies  
Despite the poor understanding behind the mechanisms of valve calcification, several 
efforts have been made to inhibit or at least decrease the extent of calcification, 
attempting to increase the durability of BHVs. Systemic therapy has been explored, 
however anti-calcification measures that are administered systemically have 
demonstrated to have a negative effect on physiological bone formation (Simionescu 
2004; Schoen & Levy 2005). Drug delivery has also been moderately explored, however 
the most attempted method to alleviate heart valve calcification is surface modification of 
biomaterials.  
For example, Ohri et al. (2004) used a subcutaneous mouse knockout model to 
demonstrate the effectiveness of grafting functionalized hyaluronic acid (HA) to the free 
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aldehyde groups in glutaraldehyde treated bovine pericardium in attempt to reduce 
calcification. They reported an 84.5% reduction in calcium in comparison to tissue that 
had not had HA modification (Ohri et al. 2004). 
A number of groups have endeavored the incorporation of ethanol in their pretreatment 
protocol. Pathak et al. (2004) used a short and long chain alcohol combination in ethanol 
buffered solution, hypothesizing this to reduce phospholipid content, thus inhibiting 
calcification potential. This was tested in rat subcutaneous model and had positive results 
(Pathak et al. 2004). Ethanol-aluminum chloride treatment was also shown to 
significantly decrease calcification in porcine valve cusps and the aortic wall when 
studied in juvenile sheep for 150 days (Clark et al. 2005). When combined with 
octanediol, ethanol pretreatment was shown to remove lipids, reduce calcification and 
uphold collagen stability when implanted in rats for 30 – 75 days (Pettenazzo et al. 2008). 
In 2011, Connolly et al. used triglycidal amine (TGA) in conjunction with ethanol to test 
for anti-calcification potential in a subdermal rat model and subsequently in a sheep 
mitral valve replacement study. Calcification resistance was achieved, however structural 
instability was also observed after 150 days of circulatory exposure (Connolly et al. 
2011). Ethanol pretreatment has been known to permanently modify the collagen 
structure in tissue, however as can be seen from select studies, combining ethanol with 
supplementary solutions can potentially allow for stability to be achieved. 
Kasimir et al. (2003) studied multiple detergents (trypsin, SDS, Triton-X 100® and 
sodium-deoxycholate) for decellularization to compare their effectiveness of cell removal 
and maintaining structural integrity. Trypsin vastly modified the structural matrix with 
incomplete decellularization; SDS was efficient in cell removal but also imposed 
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structural changes; Triton-X 100® and sodium-deoxycholate both appeared superior in 
cell removal and did not change the structure of the matrix (Kasimir et al. 2003).  
Some research groups have explored the importance of GAG stability in structural 
deterioration. A recent endeavour of such involved comparing GA treated pericardium 
with pericardium treated with higher concentrations of GAGs and with a commercial 
pericardial patch (Glycar). Using a subcutaneous rat model for 8 weeks, GA treated 
pericardium exhibited the highest levels of calcium deposition and had lower tensile 
strength. There were no significant differences between the tissues in regards to 
enzymatic degradation and immune response. Although the GAG treatment seemed to 
hold promise, unfortunately this study also revealed that the stabilization of GAGs was 
not completely effective and penetration into the pericardium was limited, therefore GAG 
leaching occurred and surrounding tissue was damaged. They concluded that this 
treatment would not be safe for clinical use (Van Den Heever et al. 2013). 
Alternative crosslinking treatments have also been employed in attempt to eliminate the 
effects of GA treatment. Some of these have included epoxy compounds, dye-mediated 
photo-oxidative reactions and carbodiimide compounds (Moore & Adams 2001; Moore et 
al. 1998). Calcification has still posed concern in these treatments, underscoring the 
multiple factors that contribute to the manifestation of calcium on heart valves. 
Research is also being conducted in search of new/alternate biomaterials. Ghanbari et al. 
(2010) suggested incorporation of a nanocomposite polymeric biomaterial. They studied 
the synthetic material polyhedral oligomeric silsesquioxane–poly(carbonate-urea) 
urethane (POSS-PCU) in comparison to bovine pericardium and also polyurethane. They 
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achieved a reduction in calcification and also maintained mechanical properties, 
suggesting that this synthetic material is superior for bioprosthetic heart valve use 
(Ghanbari et al. 2010). In 2014, Bracaglia et al. developed a different novel synthetic 
material that incorporates the use of bovine pericardium and poly(propylene fumarate) 
(PPF). Essentially, the pericardium is coated with the polymer, proposing physical 
protection from enzyme degradation while maintaining the structural matrix in its 
original form for long-term durability. This method also avoids the use of chemical 
crosslinking, evading the undesirable side effects that are known to follow. This model 
was tested in vivo using a subdermal rat model and results showed less calcification in 
the PPF reinforced pericardium. (Bracaglia et al. 2014). Using a support material could 
prove to be an effective strategy for increasing the durability of BHVs, however further 
research needs to be completed in order to evaluate the long-term efficacy and safety of 
these materials. 
As can be seen from all of the abovementioned studies, despite the abundance of different 
approaches that have been attempted, to date there is no single procedure that has made a 
significant clinical impact. It may be difficult to compare and contrast these 
methodologies, as some are targeted towards different mechanisms and although others 
may seem similar, the results are highly process dependent. As such, these successes are 
prosperous only in their focus, and combination therapies are expectedly needed to 
simultaneously address calcification of heart valves.   
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2.9 Motivation for Thesis 
Although BHVs have been in use since the 1960’s, there have been minimal substantial 
improvements in their long-term durability (Zilla et al. 2008) – this statement 
encapsulates the incentive for this research project, as it demonstrates the strong need for 
substantial developments in the field. The main focus of this thesis is on calcification, 
since it is a major cause of failure in BHVs. If we can extend the lifetime of a BHV, it 
would make a significant impact on a large patient population, which is the ultimate goal. 
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Chapter 3   
3 In vitro Quantification Methods for Calcium in Soft 
Tissue1 
 
3.1 Introduction 
Ectopic mineralization, generally referred to as the aberrant biomineralization of soft 
tissues via deposition of calcium compounds, has been linked to several clinical 
conditions, such as injury, aging, cancer, diabetes, and autoimmune diseases. Of 
particular interest in cardiovascular device development, bioprosthetic heart valves 
(BHVs) have also been shown to be prone to ectopic calcification, which has been 
attributed to be an important factor leading to their failure. (Giachelli 1999; Li & Uitto 
2013) 
Since their development, bioprosthetic heart valves (BHVs) have undergone many 
modifications in efforts to improve their reliability and durability, however none have yet 
demonstrated absolute long-term clinical success for all patient groups (Simionescu 2004; 
Schoen & Levy 2005). Patients with valvular heart disease certainly have a longer and 
enhanced quality of life due to the advances in prosthetic heart valves (when valve repair 
is not an option), however there is still substantial room and a significant need for 
optimizing BHVs. 
1 This chapter has been submitted as a manuscript as titled to the Journal of Physiological Measurements - 
Article reference: PMEA-101040. Authors:	   Asha Parekh, David W. Holdsworth, Eric Talman, Wankei 
Wan 
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One of the most frequent reasons necessitating heart valve replacement surgery is 
calcification of the heart valve leaflets (Gross 2001). The growth of calcium deposits on 
heart valves interferes with their motion leading to incomplete leaflet opening and/or 
leaflet tearing, which are conditions that may result in valvular stenosis and/or valvular 
insufficiency (Vesely 2003). Many factors contribute to calcification; and although 
calcification is a well-known phenomenon, the mechanisms behind it are not completely 
understood (Gross 2001).  
Quantifying the amount of calcium in heart valve tissue is an important aspect in this area 
of research, as the extent of calcification plays a significant role in the ultimate 
functioning of the soft tissue based devices. Imaging techniques such as Scanning 
Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM) are 
commonly used procedures to detect and confirm the presence of calcium in explanted 
tissues, medical devices and biomaterials (Vasudev et al. 2000; Bertazzo et al. 2013). The 
presence of calcium in soft tissues has also been characterized by spectroscopic methods 
such as Fourier Transform Infrared Spectroscopy (FTIR) (Delogne et al. 2007). Some 
further quantitative methods have involved measuring the calcium in solution upon 
sample hydrolysis using colorimetric methods and atomic spectroscopy (Ohri et al. 2004; 
Munnelly et al. 2012).  Among these techniques, the most commonly used approaches to 
quantify calcium in soft tissues are atomic absorption spectroscopy (AAS) and 
inductively coupled plasma spectroscopy with a mass spectrometer as a detector (ICP-
MS). However, due to the difficulties encountered in sample preparation, results reported 
show large variations (Pettenazzo et al. 2008; Steitz et al. 2002). In order to prepare soft 
tissue samples into a form that could yield useful reproducible results from AAS, ICP-
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MS or similar modes of analysis, processing that allows complete sample dissolution is 
needed. One approach that can enhance tissue sample dissolution is by increasing the 
surface area per unit sample mass. For calcium quantification within heart valve tissue, 
past efforts used in sample preparation do not define the specific procedure for “mincing” 
the tissue samples.  Gilinskaya et al. (2003), Delogne et al. (2007) and presumably others 
have employed a mortar and pestle to grind lyophilized samples. 
This study aims at developing a reliable and reproducible method to quantify calcium in 
soft tissues. Bovine pericardium that is commonly used in bioprosthetic heart valve 
manufacturing will be the tissue being investigated. Tissue samples will be processed 
using a cryo-milling procedure for quantification using AAS and ICP-MS. A novel 
methodology using µCT will be explored. This approach has the potential of 
simultaneous determination of the spatial distribution of calcium within soft tissue 
samples.   
3.2 Materials and Methods 
3.2.1 Preparation of Pericardial Tissue 
Bovine hearts with pericardium attached were obtained from a local slaughterhouse 
(Mount Brydges Abattoir, Ontario, Canada). Upon transportation to our laboratory, the 
pericardium layer was carefully removed, rinsed with cold saline solution and excess fat 
from the tissue was carefully removed. A pre-treatment step of immersion in 0.2% PBS 
buffered glutaraldehyde (GA) (t = 3-4 hours) followed by treatment with 0.5% PBS 
buffered GA (t = 2-3 days) was employed for fixation. The tissue was then cut into 3x3 
(cm) sections and placed in simulated blood plasma (SBP) solution in a temperature-
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regulated shaker bath at 37.5°C. To prepare SBP with calcium and phosphate levels at the 
same total concentration of electrolytes as present in human blood plasma, CaCl2, MgCl2, 
NaCl, K2HPO4 and NaHCO3 were dissolved in distilled water, with concentrations of 
electrolytes as follows: Ca2+ 2.5, Mg2+ 1.5, Na+ 142.0, Cl- 148.8, K+ 2.0, HPO-4 1.0,  
HCO-3 4.2 [mmol L-1]. Any unused GA treated tissue was stored in saline solution at 4°C. 
Samples were extracted from the SBP at 7 days, 14 days, 21 days. Samples were first 
analyzed under µCT and subsequently via AAS and ICP-MS. 
3.2.2 Sample Preparation for Calcium Analysis 
Bovine pericardium patches were pat dried to remove excess solution, and were then 
placed in a cryogenic mill (SPEX SamplePrep LLP., Model 6770). The patches were pre-
cooled with liquid nitrogen for five minutes and subsequently milled for one minute in 
the temperature-controlled vessel. The resulting powdered tissue was recovered from the 
sample holder and stored in vials for AAS and ICP-MS analysis. 
3.2.3 Calcium Determination by AAS  
Approximately 0.2 g of the cryo-milled samples were placed in digestion vials and 10 mL 
of aqua regia and 15 mL deionized water was added to each vial. The samples were 
digested at 120°C for approximately 2 hours upon which the milled samples completely 
dissolved. These solutions were used for calcium analysis using atomic absorption 
spectrometry (Varian Spectra AA 55). A calibration curve of calcium standard solution 
(Fluka, Sigma Aldrich) was used to convert the absorbance into concentration. Results 
are reported as grams of calcium per milligram of dry sample weight. 
56 
 
3.2.4 Calcium Determination by ICP-MS 
Approximately 0.2g of each cryo-milled sample was digested using aqua regia for 2 
hours at 95°C. The resulting solution was analyzed using an inductively coupled plasma 
mass spectrometer (Agilent 7700 Series ICP-MS).  
3.2.5 Calcium Visualization Using Micro-computed Tomography 
(µCT) 
For visualization of calcium using micro-computed tomography (µCT), whole tissue 
samples were used. Each tissue sample was mounted in a custom designed sample holder 
to hold and keep the tissue samples in place for imaging. Each sample was sandwiched 
between two rectangular foam frames and in the assembly was placed in a conical tube. 
Hot water was injected at the bottom of the tube in order to prevent tissue dehydration for 
the duration of the scan. This design allowed for the tissue and water to be separated (i.e. 
not submerged), allowing for differentiation between the two, since their x-ray 
attenuation coefficients are very similar. This design also provided more ease and 
accuracy in computing the bone mineral content (BMC). 
3.2.5.1 Imaging Parameters 
Samples were imaged using a micro-computed tomography (µCT) scanner (GE 
Healthcare, Explore Locus) with an x-ray voltage of 80kV and a current of 450 µA for 
2.75 hours. Data were acquired at a voxel size of 0.020 mm and reconstructed into a 3D 
volume at a voxel size of 0.040 mm. For clearer visualization of the mineral deposition, 
maximum intensity projection views were acquired and will be shown in the results 
section.  
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3.2.5.2 Bone Mineral Content Analysis 
With a known volume of the sample and calibration using water and synthetic bone 
material (SB3), the bone mineral content in the tissue was calculated in mg of 
hydroxyapatite (mg HA), from which the amount of calcium was computed (mg Ca).   
3.2.6 Statistical Data Analysis 
A comparison analysis of the experimental values was conducted using a one-way 
ANOVA test (Prism 6). The differences between the three methods of analysis were 
considered statistically significant for values of p< 0.05. 
3.3 Results and Discussion 
For the reliable determination of calcium contents in soft tissue using AAS or ICP-MS, it 
is critical that the tissue samples are completely digested in the digesting reagent. 
Typically, the solution is usually prepared by dissolving a known mass of dried tissue, 
such as bovine pericardium, in a known volume of a strong oxidizing acidic medium such 
as aqua regia. Although soft tissues consist mainly of proteins, their composition and 
structure vary and consequently their solubility characteristics may vary in the solvent 
used. Any component of the tissue that is not digested would lead to erroneous results in 
calcium determination. One approach that can be used to maximize tissue sample 
solubility and enhance the rate of dissolution for complete calcium release is to increase 
the surface area of a given sample size. The traditional mortar and pestle technique had 
been tried with some success (Gilinskaya 2003). A ball mill grinder is a better alternative 
as it can grind a sample into particles with sizes in the micrometer range (Gürbüz et al. 
2015). However, associated with size reduction in the ball mill grinding process, a large 
58 
 
amount of heat is generated. For soft tissue, this could lead to denaturization and 
decomposition, which can alter its digestion characteristics. In the present work, we 
chose to use a cryo-mill grinder that operates at liquid nitrogen temperature. This would 
ensure that the sample does not overheat; the tissue also becomes brittle at such a low 
temperature, which facilitates the grinding process for increased uniformity of particle 
size in sample particle production. A representative view of the tissue sample after cryo-
milling is shown in Figure 3.1. The particle size is ~1-3µm. This greatly increases its 
surface area and ensures rapid and complete dissolution for calcium determination using 
AAS and ICP-MS. 
 
Figure 3.1 Scanning Electron Microscopy (SEM) Image of Cryo-milled BP Sample 
µCT is an established method used in the determination and mapping of 
calcium/phosphorus ratio at bone sites (Speller et al. 2005; Dong et al. 2014) and imaging 
of soft tissue (Wathen et al. 2013). Recently, this method has been used to assess aortic 
calcification (Huesa et al. 2013). Another study detailed its application in pericardial 
tissue, where enhanced µCT was used to visualize the progression of calcification using a 
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subcutaneous rat model over a period of 60 days (Liu et al. 2014). It was therefore 
worthwhile to assess the possibility of using this technique to quantify calcium in soft 
tissues. The advantages of the use of µCT are that bulk tissue can be used directly without 
a multi-step sample preparation process as in the cases of AAS and ICP-MS. It would 
also allow for visualization of the spatial distribution of calcium in the tissue. Although 
quantification of calcium is fairly straightforward with µCT, depending on their sizes, 
mapping of the calcification sites may require resolutions in the range of tens of 
micrometers. For the purpose of calcium quantification only, a relatively low resolution 
and shorter scan time can be used. If visualization of the spatial distribution of the 
calcium sites is desired, a higher resolution with a longer scan time is required. Figure 3.2 
is an example of a high-resolution µCT scan, used to show the maximum intensity 
projection of each plane of a pericardium sample. 
 
Figure 3.2 Calcium Distribution in BP Using High-resolution µCT. White Spots 
Depict Calcium (arrows for examples) 
Calcium in tissue data were collected on glutaraldehyde fixed pericardium samples after 
immersion in SBP using the AAS, ICP-MS and µCT methods on a weekly basis over a 
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period of four weeks. As immersion time increases, we expect an increase in calcium 
uptake in the pericardium samples. This increase in calcium uptake over time had been 
reported extensively and was one of the procedures used to assess the relative 
calcification tendency of treated soft tissues (Mavrilas 2004). To demonstrate the 
precision and reproducibility of the analysis techniques, we chose to focus on data 
collected on day 21 of the experiment. Table 3.1 summarizes the data for all samples 
(n=6) determined with AAS, ICP-MS and µCT together with their means and standard 
deviations. As can be seen in the Table 3.1, a one-way ANOVA analysis indicates that 
there is no statistical difference (p>0.05) of the mean calcium content as determined 
using all three techniques used.  
Table 3.1 Calcium Uptake by Individual BP Samples (n=6) as Determined by AAS, 
ICP-MS, and µCT at t=21 days 
 
Method of Analysis AAS ICP-MS µCT 
Ca (ppm) 701 908 824 
 
894 974 768 
 
775 714 643 
 
592 753 569 
 
615 849 653 
 
657 1027 798 
Mean ± St Dev 705.7 ± 109.2 870.8 ± 122.8 709.2 ± 101.7 
 
The calcium uptake results of the bovine pericardium samples over the course of 28 days 
as determined by AAS, ICP-MS and µCT are shown in Figure 3.3. As expected, calcium 
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content of the tissue increased with increasing exposure time in the SBP. More 
importantly, one-way ANOVA analysis indicated that there is no statistical difference 
(p>0.05) of the mean calcium determined using all three techniques at all time points.  
 
Figure 3.3 Calcium Uptake by BP Samples Measured by AAS, ICP-MS, and µCT 
over a 28-day period, n=6 for each time point, p>0.05 
Many of the early reports on calcium in soft tissues determination were performed using 
AAS (Hassoulas, J., Rose 1988). In fact, with the ability to detect calcium in the ppm 
range, AAS was one of the first methods used for this purpose. However, due to the 
difficulty to completely digest the tissue samples, analysis results were often unreliable 
with large sample-to-sample variations. With the advent of ICP-MS, which can detect 
metals in the ppb and even ppt levels, it has also been used. The ICP-MS technique was 
often preferred as atomic mass of the isotopes of calcium, principally 20Ca, can be 
accurately detected and quantified. However, with ICP-MS, the tissue samples still have 
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to be prepared the same way as when AAS is used and consequently would suffer the 
same uncertainty due to sample digestion issues. Hence, unless the tissue samples have 
very low levels of calcium, in the ppb and lower ranges, there is no clear advantage of 
ICP-MS over AAS.  
As seen in Figure 3.3, the use of µCT for calcium determination gave results that are 
statistically equivalent to that of AAS and ICP-MS. Since no sample preparation was 
required, the procedure is highly simplified and time saving. In addition, it also provided 
information on the spatial distribution of calcium within the tissue sample (see Figure 
3.2), which is not possible using AAS or ICP-MS. This information could be invaluable 
in some instances. In bioprosthetic aortic heart valve manufacturing, calcification 
reduction treatments are often applied to the tissue used. Since one of the causes of 
failure of these valves is calcification (Lee 2009), it may be desirable to determine if their 
failure is related to the spatial distribution of the residual calcium in the tissue.  
It is interesting to note that even though statistically, the calcium quantification results are 
not different for all three methods, a closer look at Figure 3.3 revealed that the mean 
values for the ICP-MS data are systematically higher than that determined by the other 
two techniques. This is most likely due to the natural abundance of the isotope of 18Ar in 
the plasma generated, which has an identical atomic mass as 20Ca (Tan and Horlick 1986; 
Beauchemin et al. 1987). As a result, this would lead to a positive bias of calcium content 
determined in the sample and more importantly, depending on the amount of the atomic 
mass 40 18Ar isotopic is present in the plasma, a larger variation of the results.  
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Based on the results presented, all three methods we studied for calcium determination in 
soft tissues gave equally good results and can be used interchangeably. The choice of one 
method over another may depend on a number of factors such as the amount of calcium 
in the sample, requirement for determining the spatial distribution of calcium in tissue 
and other factors. The relative advantages and disadvantages of these methods are 
summarized in Table 3.2. Depending on the type of information desired, one or more of 
these three methods can be chosen.  
 
Table 3.2 Comparison of the Relative Advantages and Disadvantages of AAS, ICP-
MS, and µCT Methods for Calcium Determination in Soft Tissues 
Method Advantages Disadvantages  
AAS - Simple 
- Fast  
- Economical 
 
- Concentrations at ppm and 
higher only 
- Tedious sample preparation 
ICP-MS - Concentration as low as ppb 
and ppt level 
- Interference by atomic mass 
40 18Ar 
- Tedious sample preparation 
- Expensive  
µCT - No sample preparation 
required 
- Non-destructive 
- Spatial distribution can also 
be determined 
- Concentration at ppm level 
only 
- Expensive  
 
3.4 Conclusions 
In this chapter, we compared three different methods for the quantification of calcium in 
bovine pericardium. Methods evaluated were atomic absorption spectroscopy (AAS), 
inductively coupled plasma – mass spectrometry (ICP-MS) and micro-CT (µCT). By 
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using a cryo-miller to achieve reduction of tissue samples to micron size particles, 
consistent calcium determination using AAS and ICP-MS was achieved. Use of µCT not 
only gave consistent and reproducible results, but 3D spatial distribution in the tissue 
sample was also visualized and the sample was preserved since no cryo-milling was 
necessary. All three techniques gave results that were statistically equivalent. The choice 
of a specific method therefore is a function of calcium concentration, time required, cost 
and if calcium mapping is desired. The methods reported are useful in the assessment of 
calcification of soft tissues and in the development of improved prosthetic devices such 
as porcine and pericardial heart valves. 
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Chapter 4  
4 The Effects of Dimethyl Sulfoxide (DMSO) on 
Calcification of Bovine Pericardium 
 
4.1 Introduction 
Over time bioprosthetic heart valves (BHVs) inevitably suffer from structural 
deterioration, which primarily stems from calcification (John & Liao 2006); and although 
calcification is a well-known topic, the exact mechanisms of ectopic calcification remain 
largely unknown. Extensive research has been conducted in an effort to develop a 
treatment process that could at best eliminate, or at least significantly reduce calcification 
of soft tissue valves. Although none have fully succeeded, there have been improvements 
that have increased the long-term durability to a lifetime of approximately 10-15 years 
(Iaizzo 2013). 
Treating BHVs before implantation is indisputably necessary for the long-term success of 
the valve. The use of glutaraldehyde (GA), a highly reactive water-soluble dialdehyde, 
has been standard practice for cross-linking since its emergence in the 1960’s (Zilla et al. 
2008). GA stabilizes the collagen structure, prevents tissue digestion by enzymes or 
bacteria, and reduces the antigenicity of the material (Schoen & Levy 2005). The 
suppression of host immunological reactivity and collagen stabilization are essential 
components to the GA fixation process, however GA has also been shown to promote 
dystrophic calcification (Stones 2007).  
69 
 
Several postulations exist in attempt to explain the mechanisms of valvular calcification. 
One hypothesis is that the mineralization process in the cusps of BHVs is initiated within 
tissue cells that have been devitalized but not removed by glutaraldehyde pretreatment 
(Chandy et al. 1998; Vyavahare, et al. 1997). The physiological mechanisms that exist for 
normal extrusion of calcium ions would be disrupted in cells that have been rendered 
nonviable by glutaraldehyde fixation, leading to a much higher calcium concentration 
surrounding the valve (Simionescu 2004). Cell membranes are high in phosphorus; they 
can bind calcium and also serve as nucleation sites. Initial calcification deposits 
eventually enlarge and coalesce; the proliferation resulting in grossly mineralized nodules 
that stiffen and weaken the tissue, therefore causing malfunction in the prosthesis by 
means of stenosis, regurgitation, or both (Chambers 2014; Dweck et al. 2012). 
Furthermore, mineralization can be enhanced at the sites of intense mechanical 
deformation generated by motion, such as the points of flexion in BHVs (Vesely 2003; 
Thubrikar 1983).  
Various treatments have been tested in efforts to reduce and ultimately eliminate valvular 
calcification. Some studies have modified the standard GA chemical crosslinking 
treatment in efforts to neutralize the toxicity of aldehyde residues and/or extract lipids, by 
using GA acetals (GAA) (Jorge-Herrero et al. 2010), or by the addition of ethanol 
(Connolly et al. 2011), or by use of diphosphonates and amino oleic acid (Simionescu 
2004; Weska et al. 2010) for example. Several decellularization methods such as 
detergent and enzyme extraction (DEE), trypsin (TS), and Triton X-100 and sodium-
deoxycholate (TSD), have also been investigated to assess their cell removal efficiency, 
and their effect on mechanical properties and structure of the resulting tissue (Yang et al. 
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2009). Potentially, the extraction of cell membrane phospholipid debris and modulation 
of collagen fiber mechanical properties could result in calcification reduction and a 
device with increased durability. 
Dimethyl sulfoxide (DMSO) is a dipolar aprotic solvent that has been shown to be 
effective in improving the internal shear properties of porcine heart valve tissue (Wan & 
Boughner 1999). It has also led to a reduction in lipid content in tissue (Wan & Boughner 
1999). DMSO has been approved by the FDA for treatment of interstitial cystitis and is 
also used for cryopreservation of mammalian cells and tissue. Although pericardial tissue 
does not have a high lipid content, the processing of pericardial tissue for BHVs results in 
phospholipids containing cell debris left in the tissue. With the high phosphorous 
contents, this cell debris can act as sites for calcification (Golomb et al. 1987). DMSO 
could be an effective medium to remove the phospholipids to reduce the rate of 
calcification.  
A commonly researched method to control calcification in BHVs is the use of a 
surfactant. Various surfactants (cationic, anionic, non-ionic) and methods have been 
proposed, however their mechanism of action remains unclear (Schoen et al. 1986; 
Siddiqui et al. 2009). Some BHV manufacturers employ the use of surfactants as part of 
their BHV manufacturing process; sodium dodecyl sulfate (SDS) is an anionic surfactant, 
widely used for various purposes including emulsifying fat, as a wetting agent, and as a 
research tool in protein biochemistry. It has also been studied for use in BHVs in an 
effort to reduce calcification (Collatusso et al. 2012; Mendoza-Novelo et al. 2011). 
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The goal of this study was to evaluate and compare the efficacy of DMSO and SDS as 
anti-calcification treatments for GA fixed bovine pericardium (BP) using an in vitro 
model. The effects of the treatment protocols were characterized in terms of calcium 
uptake over a 28-day period using µCT imaging, and mechanical testing was performed 
to evaluate the tissue tensile properties. 
4.2 Materials and Methods 
GA was purchased from Electron Microscopy Sciences, DMSO was obtained from 
Caledon Laboratory Chemicals and SDS was purchased from Sigma Aldrich (St. Louis, 
MO, USA). All chemicals purchased were of reagent grade. Saline solution (SS), 
phosphate buffer solution (PBS) and simulated blood plasma (SBP) were made in our 
laboratory as per Appendix A. Distilled water was used when required for all 
experiments. 
4.2.1 Pericardium Processing 
Bovine pericardium (fresh and 0.2% GA fixed) was obtained from Sorin Group Inc. and 
was processed as detailed in Chapter 3 (3.2.1). 
4.2.2 Treatment Protocols 
Four treatment protocols were investigated and samples were categorized into groups as 
follows:  
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Group A: 0.2% GA (t = 3-4 hours) + 0.5% GA (t = 2-3 days);  
Group B: 40% DMSO (t = 24 hours) + 0.2% GA (t = 3-4 hours) + 0.5% GA (t = 2-3 
days);  
Group C: 0.2% GA (t = 3-4 hours)  + 40% DMSO (t = 24 hours) + 0.5% GA (t = 2-3 
days);  
Group D: 0.1% SDS (t = 24 hours) + 0.2% GA (t = 3-4 hours)  + 0.5% GA (t = 2-3 days) 
All treatments were done by zero pressure immersion. Post-fixation, the tissue was cut 
into 3x3 (cm) sections and placed in SBP solution (Appendix A). Calcification testing 
was first conducted under zero pressure using a shaker bath and subsequently in a custom 
designed and constructed pressurized apparatus (Appendix B), both temperature 
regulated in a bath at 37.5°C. Excess treated tissue was stored in SS (short-term) or GA 
(long-term) at 4°C. Samples were extracted from the SBP at 7 days, 14 days, 21 days and 
28 days for analysis. Six samples were collected at each time point for determination of 
the statistics of the treatment data. 
4.2.3 Design of Pressurized System 
In order to better simulate the heart environment, we designed and built a pulsatile 
system. This system generates a pressure difference of 40 mmHg at a frequency of 60Hz 
and subjects the tissue to the calcium containing SBP. Details of this system can be found 
in Appendix B. 
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4.2.4 µCT Imaging and Calcium Quantification 
A sample holder was assembled to conduct µCT imaging as described in Chapter 3 
(3.2.5). The setup of the sample holder is shown below in Figure 4.1 below. 
 
 
Figure 4.1 BP Sample Holder for µCT Imaging 
4.2.4.1 Data Acquisition Procedure 
µCT images were acquired as described in Chapter 3 (3.2.5.1) 
4.2.4.2 Calcium Quantification 
The amount of calcium deposited on the tissue samples was calculated as described in 
Chapter 3 (3.2.5.2). 
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4.2.5 Mechanical Testing 
4.2.5.1 Sample Preparation 
Tissue samples were cut into 5x15 mm strips for tensile testing. A previously built 
custom tissue grip using sand paper was used to keep the tissue in place without slipping 
during testing. Thickness of the tissue samples was measured using an in-house built 
Mitutoyo gauge (Gordon, MJ. 1999).  
4.2.5.2 Uniaxial Tensile Testing 
The tensile properties of the tissue were measured using a servo-hydraulic uniaxial 
material testing system (Instron Model 8872). This system is equipped with a 1 kg load 
cell and has an interface to a computer system for control and data acquisition. The 
tensile testing procedure was adapted from previous work done in our lab (Millon, L.E. 
2006). Samples were placed with a 10 mm distance between the grips in order to keep the 
distance between the two grips constant. Cyclic testing at a crosshead speed of 40 mm/s 
under pre-tension conditions was applied, corresponding to systolic and diastolic 
pressures. A sine excitation wave with a sampling rate of 1Hz was used, with amplitude 
of 1.5mm. 10 cycles of pre-conditioning were carried out in order to remove any residual 
stress in the tissue. 
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4.2.6 Statistical Data Analysis 
A two-way ANOVA test (Prism 6) was performed on the calcification uptake data and a 
one-way ANOVA test (Prism 6) was used to compare the tensile testing results. The 
results for both tests were considered statistically significant for values of p<0.05. 
4.3 Results and Discussion 
4.3.1 Comparison of Calcification Rates 
The composition of calcium in all samples was analyzed using atomic absorption 
spectroscopy (AAS), inductively coupled plasma spectroscopy with a mass spectrometer 
as a detector (ICP-MS), and µCT. Based on our findings in Chapter 3, only µCT results 
are reported in this chapter. The corresponding AAS and ICPS results can be found in 
Appendix C.  
Upon subjecting the pericardial samples to SBP, the amount of calcium in the tissue 
continually increased over the 28-day period, as expected. In both zero pressure and 
pressurized experiments, Group B accumulated approximately 50% less calcium 
compared to Group A (Figures 4.2 and 4.3) by the end of the 28-day period. Beyond the 
7-day time point, the results between the two groups are statistically significant (p<0.05). 
The reduction in calcium in the DMSO treated samples is hypothesized to be attributed to 
the removal of phospholipid content and cell debris from the tissue. While the relative 
difference in calcium uptake between Group A and Group B samples are similar after 28 
days, the difference between the zero pressure and pressurized experiments can be seen in 
the amount of calcium in the treated tissues, as the values acquired in the pressurized 
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samples are approximately four times those obtained using zero pressure. This is 
indicative of the role of mechanical stresses on calcification as has been reported in the 
literature (Rayner et al. 2014). 
 
Figure 4.2 Calcium Uptake in GA and DMSO treated BP, Zero Pressure, p<0.05 
 
Figure 4.3 Calcium Uptake in BP for Groups A, B, 40 mmHg pressure, p<0.05 
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Upon completion of pressurized tests for Groups A and B, we decided to see if there was 
an observable effect on the order of steps in the treatment protocols. We therefore added 
Group C, a third treatment protocol for which the first two steps in Group B were 
reversed, giving a treatment of: 0.2% GA + 40% DMSO + 0.5% GA. The results are 
shown in Figure 4.4 and indicate that implementing the DMSO treatment after GA 
(Group C) yields a lower effectiveness in calcification reduction. Again, beyond the 7-
day time point, the results between the three groups are statistically significant (p<0.05). 
We believe that the initial 0.2% GA crosslinking could inhibit the DMSO from 
effectively removing the cell debris and phospholipid content, yielding a higher number 
of potential calcification sites and thus a higher extent of calcification at each time point. 
 
Figure 4.4 Calcium Uptake in Groups A, B, C, 40 mmHg pressure, p<0.05 
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Based on the results obtained from Group C as compared to Group B, we decided to 
subsequently investigate the use of surfactant (SDS) as a first step in the treatment 
protocol for Group D. The results are presented in Figure 4.5 and as can be seen, the use 
of SDS did suppress calcification better than Groups A and C, however it was not as 
efficient as Group B. We would expect an improved result compared to Group C, since 
the tissue had not undergone initial GA crosslinking, allowing for improved effectiveness 
of the surfactant. The proposed mechanism of action for SDS is similar to that of DMSO, 
namely the removal of phospholipids (Vyavahare, PhD et al. 1997; Hirsch et al. 1993). 
This implies that either DMSO is simply more effective than SDS, or that there is another 
mechanism in effect that is enhancing the efficiency of DMSO. Investigating a treatment 
protocol that employs both DMSO and SDS to observe whether there is an additive effect 
could lend further insight into the mechanisms. 
 
Figure 4.5 Calcium Uptake in BP for Groups A, B, C, D, 40 mmHg, p<0.05 
0	  1000	  
2000	  3000	  
4000	  5000	  
6000	  7000	  
0	   7	   14	   21	   28	  
Ca
	  (p
pm
)	  
t	  (days)	  
Group	  A	  Group	  B	  Group	  C	  Group	  D	  
79 
 
Figures 4.2 - 4.5 demonstrate that standard GA crosslinking (Group A) induced the 
highest extent of calcification, followed by GA-DMSO-GA and SDS-GA-GA treatments 
(Group C and Group D) and subsequently DMSO-GA-GA treatment (Group B). As with 
the previous studies, statistically significant differences between the four treatment 
groups were observed beyond the 7-day time point (p<0.05). From these experiments it 
can be seen that although GA crosslinking may be necessary, it is not an effective means 
to keep calcification at a minimum. This is consistent with reports in literature (Butany et 
al. 2011). There are pre-treatment steps that can be employed to assist in calcification 
reduction, such as the use of DMSO and/or SDS. Of note is that even with these pre-
treatment steps there is still an uptake of calcium that occurs.  This could be for a number 
of reasons. The residual effects of GA toxicity could play a role in calcification (Bonucci 
2007; Iaizzo 2013). Another detail is that these treatments are specifically targeting the 
cell debris in the tissue and there are plausibly additional calcification mechanisms in 
effect, since there are many potential contributing factors to soft tissue calcification 
(Schoen & Levy 2005; Simionescu 2004). The fact that there is also an initial amount of 
calcium present on the tissue reasonably also has an influence on the rate of calcification, 
since calcium deposits continue to grow and coalesce with time. Although both zero 
pressure and pressurized samples show similar trends in calcification, the pressurized 
experiments that simulate one aspect of physiological conditions indicate a significant 
increase in calcium uptake, about four folds, after 28 days. This illustrates the importance 
of further experiments under realistic physiological conditions.  
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4.3.2 Calcium Distribution in BP  
As shown in Chapter 3, µCT imaging can be used not only to quantify calcium in soft 
tissues, but also to visualize its distribution in the samples. To show the extent of 
calcification in the tissue samples can be visually realized, examples of µCT images of 
samples from Groups A, B and D are shown in Figures 4.6 - 4.8. It can be seen that in 
addition to the difference in calcium concentration, there is also a difference in the 
distribution of calcium in the tissue between Group B and Group D. In Group B, the 
calcium is quite uniformly distributed throughout the cross-section of the tissue sample. 
In Group D, more calcium appears to stay closer to the surface of the sample (Figure 4.8). 
A point of interest was that by visual inspection it was evident that Group D (SDS-GA) 
treated tissue was thicker than the other groups. In this regard, we hypothesize that the 
observed difference could at least be partially attributed to the tissue swelling effect of 
SDS treatment. Swelling may allow more effective penetration of the surfactant into the 
tissue and consequently be able to more effectively remove the calcium in the center of 
the tissue. Going forward, this could be tested by exploiting a mild shaking mechanism 
during treatment since the pre-treatment steps in these experiments were all carried out 
by simple immersion. This has been employed in previous studies, however, for 
comparison purposes, we sought to carry out all of our experiments using the same 
conditions and therefore chose not to elicit any agitation mechanism.  
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Figure 4.6 µCT Image of Sample from Group A Treatment Protocol, 40 mmHg, 
White Spots Indicate Sites of Calcium Deposition 
 
Figure 4.7 µCT Image of Sample from Group B Treatment Protocol, 40 mmHg, 
White Spots Indicate Sites of Calcium Deposition 
 
Figure 4.8 µCT Image of Sample from Group D Treatment Protocol, 40 mmHg, 
White Spots Indicate Sites of Calcium Deposition 
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4.3.3 Tensile Property Testing  
Uniaxial tensile testing was performed in order to assess the tensile strength of the treated 
tissues. An exponential model with two fitting parameters was used to fit the data 
(equation 4.1). 
            𝜎  =  𝐴exp(𝐵𝜀)                          (4.1)  
 
 
Figure 4.9 Fitted Stress-Strain Curves for Groups A, B, C, D, t=28 days, p>0.05 
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Figure 4.9 indicates that there are no significant differences regarding the tensile strength 
among the treatment groups. This is demonstrated statistically for all data points, across 
the full strain range (p>0.05). This can be due to a number of reasons. It is possible that 
the calcium deposits do not drastically affect the tensile properties. It is also possible that 
the time frame employed limits the extent of calcification and therefore no differences are 
seen. Longer testing times could be evaluated in the future to further explore these 
assumptions. Another important mechanical stress that is endured by the heart valve 
leaflets is shear stress (Talman & Boughner 1996); as the tissue leaflets undergo 
repetitive bending, there is cyclic internal shearing that occurs (Balachandran et al. 2011). 
Although these mechanical properties have not been evaluated in this study, this is a 
consideration for future mechanical testing that can be performed. 
 
4.4 Conclusions 
In this study, we have examined the anti-calcification potentials of DMSO and SDS on 
GA treated bovine pericardium. Pericardial patches were pre-treated with GA, DMSO 
and SDS (Groups A, B, C, D) and successively analyzed visually and quantitatively using 
µCT. The results showed that DMSO pre-treatment as the first step (Group B) is most 
effective in decreasing calcium accumulation compared to DMSO as a second step 
(Group C) and also in comparison to the use of a surfactant, SDS (Group D). Groups B, 
C, and D were all superior in anti-calcification efficacy compared to tissue that had only 
had GA treatment (Group A). We have also revealed the distribution of calcium 
deposition in the pericardial tissue samples, demonstrating the variation in dispersion of 
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calcium residuals, which indicates that the distribution of calcium within the tissue could 
be treatment dependent. Further testing of these protocols, namely Group B and Group D 
and their combination, could potentially increase the durability of BHVs currently in use. 
As previously mentioned and demonstrated in this study, GA treatment alone does not 
mitigate calcification. Since this study demonstrated that DMSO treatment is the most 
effective in reducing the rate of calcification; further validation of its effect should be 
conducted. Incorporation of this treatment procedure could be implemented in the 
pericardial heart valve manufacturing procedure to increase its lifespan.  
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Chapter 5  
5 Forms of Calcium Present in Fresh and GA-Fixed 
Bovine Pericardium 
5.1 Introduction 
Most soft tissues, including cardiovascular tissue, can undergo calcification. In the heart, 
the valves are particularly prone to calcification. The growth of calcium deposits on the 
valve cusps limits their motion, which causes tearing that results in valvular stenosis 
and/or valvular deficiency (Martin 2013; Singhal et al. 2013) Aortic valve stenosis is the 
most common among all valve diseases and the ultimate definitive treatment is valve 
replacement (Dweck et al. 2012). Among the two common types of replacement valves 
(mechanical and bioprosthetic), the mechanical valve has good durability but is 
procoagulant and prothrombotic; thus necessitating long term anticoagulation therapy, 
which limits its use (Pibarot & Dumesnil 2009). The majority of bioprosthetic heart 
valves (BHVs) are fabricated from chemically crosslinked bovine pericardium (BP) and 
porcine heart valve cusps; and even though they are thromboresistant and possess better 
hemodynamics they have higher failure rates and a shorter lifespan than mechanical 
valves (Schoen & Levy 2005; Simionescu 2004). Failure is most often attributed to 
calcification of the tissue in BHVs (Giachelli 1999; Li & Uitto 2013). This further 
highlights the need to have a better understanding of the nature of the tissue, which could 
allow for the development of optimal methods to control and reduce calcification in soft 
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tissues of both human and animal origin. For BHVs, such as the pericardial BHV, this 
could lead to enhanced durability and benefits to patients. 
Since calcification is the most common reason for BHV deterioration and eventual failure 
(Gross 2001), many efforts have been concentrated in attempting to diminish mineral 
deposition. Various treatment procedures have been explored and employed in 
commercial BHV production. These include the use of surfactants, such as sodium 
dodecyl sulfate (SDS) (Den et al. 2006); solvents, such supercritical CO2 (Kafesjian & 
Howanec 2001); and the use of a combination of surfactants and solvents, such as Tween 
80 and ethanol (Nashef & Ahmed 1993). There are also numerous research studies that 
have investigated anti-calcification treatments in efforts to increase BHV durability (Ohri 
et al. 2005; Zilla et al. 2008; Siddiqui et al. 2009). Despite all these efforts, there is no 
conclusive evidence of increased durability.  
Ectopic calcification in BHVs entails the possibility of several mechanisms in action. 
Previous studies have revealed that heart valve calcification is not likely to be a passive 
process as previously thought, but more of an active process that is regulated by cellular 
mechanisms (Stones 2007; Ronchetti et al. 2013). In the case of BHVs, post-implantation 
calcification could be due to several different mechanisms.  In addition to the inevitable 
immune response by the body at the site of implantation (Manji et al. 2014), 
glutaraldehyde (GA), the most commonly used crosslinking agent for BHV tissues, has 
also been implicated in inducing calcification. This relates to the normal physiological 
mechanisms to regulate calcium being interrupted, and the increase in calcium 
concentration being exposed to high phosphate levels in blood serum causes precipitation 
of calcium phosphate minerals (Giachelli 1999; Stones 2007). The toxicity of GA has 
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also demonstrated to potentially cause calcification by damaging the tissue, allowing for 
sites of dystrophic calcification (Weska et al. 2010). Studies have shown that there is a 
quantitative relationship between the amount of GA and calcium deposits (Lee 2009). In 
addition, various components and locations of functioning BHVs are continuously under 
different forms of stress, such as tension, compression and flexure (Balachandran et al. 
2011). Areas that are under higher mechanical stresses have been shown to also have a 
higher degree of mineralization (Vesely 2003) . 
Despite the fact that BHVs have been in use for almost 50 years, the durability of these 
valves has essentially remained unchanged (Zilla et al. 2008). This points to an 
inadequate understanding of the critical mechanisms of BHV failure and in particular, 
calcification of tissues such as bovine pericardium and porcine heart valves. Interestingly, 
since it is well established that calcium is present in various forms of phosphates in 
human soft tissues (most prominently calcium hydroxyapatite) (Bertazzo et al. 2013; 
Ronchetti et al. 2013), there is an implicit assumption in the literature that one can safely 
accept that calcium also exists in similar chemical forms in animal tissue such as bovine 
pericardium. This would imply that the mechanism of continuous calcification in BHVs 
post-implantation is closely parallel to that of calcium hydroxyapatite (HA) formation. 
However, if the chemical forms of calcium present in these tissues are not the same or 
similar to those present in human soft tissues, the eventual chemical forms and their rate 
of deposition could be different. More importantly, the approaches currently used to 
control calcium content and its deposition in BHV may not be optimal.  
In this study, we investigated the morphology, the chemical composition, and the 
possible forms of calcium that are present in fresh and GA treated BP. Implications of 
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these results in terms of mechanisms and how they potentially contribute to BHV 
calcification under physiological conditions will be discussed.  
5.2 Materials and Methods 
5.2.1 Preparation of Pericardial Tissue 
Bovine hearts were obtained as described in Chapter 3 (3.2.1) and several tissue patches 
were excised for analysis. Analysis was conducted on fresh pericardium and GA treated 
pericardium (as described in Chapter 4, Section 4.2.2, Group A). The cows (n=6) were all 
aged between 24-32 months.  
5.2.2 Sample Dehydration 
Each BP sample was dried by successive solvent exchange in water and ethanol (50%, 
70%, 80%, 90%, 95%, 100%, 100%). Samples were subsequently placed in a closed 
environment for 24 hours to allow for ethanol evaporation and complete drying prior to 
analysis. 
5.2.3 Scanning Electron Microscopy (SEM)  
To assess the morphology and microstructure of calcium deposits on the tissue, images 
were obtained using a Leo 1530 scanning electron microscope at an accelerating voltage 
ranging between 2~10 kV.  
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5.2.4 Energy Dispersive X-ray (EDX) Spectroscopy 
In order to determine the chemical composition of the calcium deposits on the tissue 
samples, elemental analysis was conducted using an energy-dispersive x-ray 
microanalysis system that is connected to the SEM machine. Using the backscatter mode 
on the SEM, elemental analysis was performed on chosen regions of interest. 
5.2.5 X-Ray Diffraction (XRD) 
In an effort to identify the crystalline structures found in the tissue, samples were 
dehydrated as described in Section 5.2.2 and x-ray diffraction (XRD) was performed. 
XRD analysis was conducted using a Rigaku-Rotaflex Diffractometer (RU- 200BH) with	  
Co-kα radiation (λ =1.79 Å) at 30kV and 44mA. Spectra with a 2θ diffraction angle were 
acquired using a 0.02° step size. Spectra were	  plotted	  for 2θ	  values of	  5° to 82°. 
5.3 Results and Discussion 
Bovine pericardium that is excised for BHV fabrication is a two-layered structure 
comprised of approximately 90% type I collagen, with some elastin, glycosaminoglycans 
(GAGs) and glycoproteins. The inner surface is known as the (parietal) serous 
pericardium, whereas the outer surface is referred to as the fibrous pericardium (Figure 
2.4) (Iaizzo 2009; Rémi et al. 2011). Figure 5.1 illustrates the characteristic banding 
structure of collagen found in bovine pericardium. Despite any structural differences 
between bovine pericardium and native human heart valve tissue, several studies that 
have investigated ectopic calcification have proposed that the mineralization in both 
tissues is similar in nature to bone formation (Bonucci 2007), implicating calcium 
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phosphate crystals forming apatite (namely HA) of poor crystallinity along collagen 
fibers (Bertazzo et al. 2013). These studies have shown that the elemental composition of 
calcium deposits is similar to that of bone mineral.  
 
 
Figure 5.1 Collagen in Fresh BP Sample 
 
Our studies using high resolution SEM of fresh and GA fixed pericardium showed 
multiple sites of calcific deposits on the tissue, with a broad range of morphology.  
Figures 5.2a, 5.4a and 5.6a are typical of the morphologies observed. There were sites of 
mineralization that resembled typical HA (Figure 5.4a), but of the most interest were the 
apparent clusters of well-defined crystals with a hexagonal cross-section of ~200 nm and 
length of ~100 to 500 nm (Figure 5.2a, additional images are in Appendix D). Previous 
studies of soft tissues, including BHV materials, have invariably reported calcium 
morphologies similar to that shown in Figure 5.4a with ill-defined crystal morphology 
(Cottignoli et al. 2015). The discovery of deposits shown in Figure 5.2a with apparent 
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highly crystalline morphology is therefore rather unexpected. EDX analysis on our 
samples indicated the presence of calcium in various forms, shown in Figures 5.2b, 5.4b 
and 5.6b. A range of compositions was found, such as phosphate-based calcium 
(including HA-like), sulfur-based calcium (including calcium sulfate-like (CS)) and 
compositions that were consistent with a mixture of calcium (Ca), sulfur (S), and 
phosphorus (P). The hexagonal crystal clusters invariably had a composition very close to 
that of CS. The most interesting results, as shown in Figure 5.3, is that the EDX spectrum 
showed the presence of calcium and sulfur, but no phosphorus. This can be contrasted 
with the EDX results shown in Figure 5.5, where calcium is present together with 
phosphorus as expected of HA type of calcification. EDX shown in Figure 5.7 is a 
calcium-containing site where calcium is present together with both sulfur and 
phosphorus. Details of the EDX analysis are collected in Tables 5.1, 5.2 and 5.3 below. 
 
      
Figure 5.2 a) High Resolution SEM Image of Hexagonal Calcium Crystals in BP b) 
Image Indicating Region Selected for EDX Analysis	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Figure 5.4 a) SEM Image of Phosphorus-Based Calcium Mineralization in GA-fixed 
BP b) Image Indicating Region Selected for EDX Analysis 
 
 
      
 
 
 
Figure 5.3 EDX Analysis of Hexagonal Crystals in Figure 5.2 Indicating the 
Presence of Calcium and Sulfur 
Figure 5.5 EDX Analysis of Mineralization Site in Figure 5.4 
Indicating Presence of Calcium and Phosphorus 
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Figure 5.6 a) SEM Image of Mineralized Site of Mixed Composition in GA-fixed BP 
b) Image Indicating Region Selected for EDX Analysis 
 
 
 
 
 
 
Similar to many types of soft tissue in humans and animals that have been studied, we 
found the presence of calcium with compositions and morphologies similar to HA 
(Figure 5.4a/b). In addition to these calcification sites, we have also identified sites 
containing calcium in association with sulfate (Figure 5.2a/b). This is rather unexpected, 
as we are not able to find any report of its existence in soft tissue in the literature. The 
presence of this form of calcium in bovine pericardium suggests that there may be an 
entirely different mechanism in effect during the initiation of ectopic calcification in 
Figure 5.7 EDX Analysis of Mineralization Site in Figure 5.6 
Indicating Presence of Calcium, Sulfur, and Phosphorus 
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BHVs than that which occurs in human heart valves (Bertazzo et al. 2013). Moreover, 
this could also be a reason why the current methods used in calcification reduction for 
BHV manufacturing may not be the most effective. 
 
One common form of a sulfur-containing calcium compound is calcium sulfate. Calcium 
sulfate exists in three different crystallized forms: anhydrous, dihydrate, and 
hemihydrate. Phosphorus-containing calcium compounds that are commonly associated 
with tissues are calcium hydroxyapatite and calcium-deficient hydroxyapatite (Bertazzo 
et al. 2013; Cottignoli et al. 2015). Chemical formulas and abbreviations of these calcium 
compounds are shown below. 
 
Calcium sulfate anyhydrous (CSA) - CaSO4 
Calcium sulfate dihydrate (CSD) - CaSO4.2H2O 
Calcium sulfate hemihydrate (CSH) - CaSO4.0.5H2O, 
Hydroxyapatite (HA) - Ca10(PO4)6(OH)2 
Calcium-deficient hydroxyapatite (CDHA) - Ca9(PO4)5(HPO4)OH 
 
A comparison of the Ca/S, Ca/O and S/O ratios determined from the EDX results in 
Figure 5.3 and those calculated for the three different calcium sulfates indicate that the 
results are consistent with a calcium compound that could be either CSA or CSH. On the 
other hand, results shown in Table 5.2 is consistent with that of some form of calcium 
HA, possibly a mixture of HA and CDHA. Results in Table 5.3 show calcification sites 
that have Ca/S and Ca/P ratios that are neither CS nor HA, but rather possibly mixtures of 
sulfur and phosphorus containing calcium compounds. 
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Table 5.1 Comparison of Ca/S, Ca/O, S/O Ratios Between BP Sample in Figure 5.2 
and Forms of CS 
	  	  
Fresh	  BP	  
Sample	   	  CSA	   	  CSD	   	  CSH	  
Ca/S	   1.11	   1	   1	   1	  
Ca/O	   0.23	   0.25	   0.17	   0.23	  
S/O	   0.2	   0.25	   0.2	   0.22	  
 
Table 5.2 Comparison of Ca/P, Ca/O, P/O Ratios Between BP Sample in Figure 5.4 
and HA, CDHA 
	  	  
GA-­‐Fixed	  
	  BP	  Sample	   	  HA	   	  CDHA	  
Ca/P	   1.65	   1.67	   1.5	  
Ca/O	   0.56	   0.38	   0.36	  
P/O	   0.34	   0.24	   0.24	  
 
Table 5.3 Elemental Ratios of BP Sample in Figure 5.6 with Mixed Composition 
	  
GA-­‐Fixed	  
BP	  Sample	  
CSA	  
	  
CSD	  
	  
CSH	  
	  
Ca/S	   1.42	   1	   1	   1	  
Ca/O	   0.037	   0.25	   0.17	   0.23	  
S/O	   0.026	   0.25	   0.2	   0.22	  
	   	   	   	   	  
	   	  
HA	   CDHA	  
	  Ca/P	   0.44	   1.67	   1.5	  
	  P/O	   0.083	   0.24	   0.24	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The large variation of the Ca/P/S ratio as found in many sites of mineralization (such as 
Figure 5.6, Table 5.3) is an indication that calcium phosphates and CS can possibly co-
crystallize. Recent studies in bone regeneration indicated that in the presence of 
phosphate ions, CS can react with phosphate by gradual dissociation to form various 
forms of phosphate based calcium structures, including HA structures (Bohner 2004; 
Thai & Lee 2010). There are also various studies that demonstrate several forms of 
phosphate-based calcium can precipitate into HA and CDHA, and that forms of CS are 
inter-convertible (CSA - CSD - CSH) depending on the environmental conditions (Azimi 
et al. 2007; Bohner 2004; Thai & Lee 2010; Nilsson et al. 2002). These studies 
demonstrate that the CS found in fresh and GA-fixed bovine pericardium could undergo 
conversions to form various calcium compounds, including HA, which could eventually 
grow and plausibly contribute to failure of BHVs.  
XRD analysis was performed in efforts to identify the forms of calcium present in the 
fresh and GA-fixed tissue. However, due to the high organic component of the samples, a 
diffuse background was obtained. This is due to the large ratio of collagen to calcium in 
fresh tissue, making it difficult to discern intensity peaks. Some possible peaks may 
correlate to calcium sulfate and further testing will be conducted. 
The presence of these discovered calcium sulfate crystals, shown in Figure 5.2a, could be 
related to the fairly high level of sulfur in beef cattle feed and water in various forms, 
such as elemental sulfur, sulfates, and sulfuric acid (Drewnoski et al. 2012; Drewnoski et 
al. 2014; Crawford 2007). Also the digestion, absorption and eventual metabolism of 
sulfur in cattle may be very different from that in humans. The presence of CS in bovine 
pericardium could also possibly be a way for the cow to create a reservoir of calcium in 
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its body whenever it is needed for repair or regeneration in the form of HA. It is 
interesting to note that the presence of sulfate in humans is often associated with renal 
disease and malfunctioning of the kidney, but the pericardium samples we studied were 
from healthy cows of 24 – 36 months old; this indicates that the presence of some level of 
sulfate in cows, and in particular soft tissue such as pericardium, is not detrimental to 
their health. Evidently, cows are able to tolerate the presence of calcium in the form of 
sulfate in their tissue. 
In the pericardial heart valve industry, fixation with GA of BP is an invariable processing 
step. Our results indicated that in addition to the phosphate containing calcium salts, the 
CS identified also survived the fixation process. If the tissue we investigated is typical, 
and there is no reason to believe it is not, the CS will survive the GA treatment step and 
be left in the pericardial heart valve. It has been shown that phosphate ions can interact 
with CS and results in its gradual substitution, leading to the formation of calcium 
compounds with varying ratios of S and P and eventually phosphates, including HAs. 
This implies that CS can act as sites for calcification in pericardial valves. This would be 
in addition to the conventional calcium HA-containing calcification sites. The impact on 
pericardial heart valve durability and therefore patient benefits are unknown, but quite 
possibly not positive. 
Current techniques in calcification control of pericardial BHVs use either surfactant or 
solvent treatments or a combination of both. These approaches are based on the 
assumption that calcium is present in the form of phosphates, mainly calcium HA, which 
the current study demonstrates may not be the case. In order to make meaningful 
advances in improving bovine pericardial BHV durability, we need to take into account 
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the presence of calcium in the form of sulfate in the pericardial tissue when evaluating 
potential anti-calcification strategies.  
 
5.4 Conclusions 
In this chapter, we have microscopically examined fresh and GA treated BP for the 
presence of calcium and examined the various forms of calcium mineralization. Samples 
were examined under high-resolution SEM to study the morphology of the calcium 
structures, and backscattered electron mode was used in conjunction with EDX to 
determine their elemental composition. This study revealed the presence of sulfur-based 
calcium compounds, most likely calcium sulfates, in addition to the conventional HA 
type calcium phosphates. An important aspect to consider is that GA treatment did not 
remove these sulfates that could act as sites for calcification in pericardial BHVs. Any 
future strategy in calcification reduction and durability increase in pericardial heart valve 
would have to take this into account.  
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Chapter 6  
6 Discussion, Conclusions and Future Work 
6.1 Discussion  
With the lifetime of BHVs currently at approximately 10-15 years (Siddiqui et al. 2009), 
there is a need to improve their durability. Since calcification is a major cause of BHV 
failure, anti-calcification treatments seem promising to increase their durability and hence 
have been the focus of many BHV manufacturers and research studies (Schoen & Levy 
2005; Simionescu 2004). If the rate of calcification in BHVs can be reduced, the impact 
would be significant as this could increase the patient population considered for BHV 
replacement. In this study, we focused on the calcification of bovine pericardial 
bioprosthetic heart valves by: examining methods of calcium analysis in soft tissue, 
exploring potential anti-calcification treatment protocols, and investigating the different 
forms of calcium present in fresh bovine pericardium. 
We have successfully demonstrated that the quantity of calcium in soft tissue can be 
measured using AA, ICPS, or µCT interchangeably yielding reliable results, with µCT 
allowing for visualizing the spatial distribution of calcium within the tissue. This allows 
for substitutable use of these methods, depending on the desired result and available 
options to a researcher. 
We have also determined that the order of chemical treatments applied to the tissue has 
an effect on the extent of calcification, and that the use of DMSO and SDS can 
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potentially reduce calcification appreciably. The use of DMSO prior to GA treatment 
yielded the best results (approximately 50% reduction in calcium uptake), indicating that 
this could be a suitable treatment protocol to investigate further for use in BHV 
fabrication.  
While examining bovine pericardium under high magnification, we discovered a wide 
range of calcific deposits on the fresh tissue and GA treated tissue. These consisted of a 
large number of sulfur-based calcium precipitates, including hexagonal calcium crystals 
that are not reported in literature, some phosphorus-based calcium precipitates, and some 
calcium precipitates with the presence of both sulfur and phosphorus. This revelation 
could lead to a significant decrease in calcification in BHVs, if the sulfur-based calcium 
can be targeted and removed or reduced.  
In conclusion, we have studied a few aspects related to the calcification of bovine 
pericardial BHVs, hoping that these revelations assist, influence, and expedite the much-
needed improvements to BHV durability. 
6.2 Limitations 
Limitations of this study include that we were not particularly selective in the 
pericardium used for testing. This is important since location on the pericardium selected 
influences the tissue properties due to its anisotropic nature. It also has a clinical 
significance since in reality, valve manufacturers are extremely selective of the portions 
of pericardium used and thickness is a key criteria used for selection. The use of an in 
vitro model also imposes a limit on this study, as it does not accurately depict what 
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transpires under physiological conditions. Additionally, the 28-day time consideration of 
this model does not necessarily mean that the results would be equivalent for a longer 
time period.  
6.3 Future Work 
In terms of future work, there are several aspects from this study that could be 
investigated further. With regards to the calcification reduction study carried out in 
Chapter 4, we could investigate the use of a treatment protocol that employs both DMSO 
and SDS to determine whether we could further enhance the anti-calcification effect. We 
could also consider additional mechanical testing methods beyond tensile testing. 
Furthermore, based on the best results, we could build prototype BHVs and test their 
durability in a left ventricle simulator. Subsequently, the next logical step would be the 
use of an animal model to determine their durability in vivo.  In terms of the study 
performed in Chapter 5, we would like to continue to explore the different forms of 
calcium present in fresh bovine pericardium by: further endeavouring to characterize the 
calcific deposits, increasing the number of samples, and expanding the sources of 
pericardium. 
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Appendices  
Appendix A: Preparation of Solutions 
Saline Solution (SS) 
 
Chemical Name  Mass (g) 
Sodium chloride (NaCl) 9 
 
The chemical was added to distilled water to make a final volume of 1L of SS. 
 
 
Phosphate Buffer Solution (PBS) 
 
Chemical Name  Mass (g)  
Potassium phosphate (KH2PO4) 2.4 
Potassium chloride (KCl) 2 
Sodium chloride (NaCl) 80 
Sodium phosphate dibasic heptahydrate (Na2HPO4·7H2O)  26.8 
 
 
The listed chemicals were added to distilled water to make a final volume of 1L stock 
10x PBS solution. The solution was diluted as necessary before use. 
 
 
Simulated Blood Plasma Solution (SBP) 
 
Chemical Name  Mass (g)  
Potassium hydrogen phosphate (KH2PO4) 0.1742 
Potassium chloride (KCl) 0.2238 
Sodium chloride (NaCl) 8.0613 
Sodium bicarbonate (NaHCO3)  26.8 
Calcium Chloride (CaCl2) 0.2778 
Magnesium Chloride (MgCl2) 0.143 
 
The listed chemicals were added to distilled water to make a final volume of 1L SBP 
solution. 
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Appendix B: Details of the Design and Construction of Apparatus Used 
for Pressurized Testing 
In order to mimic 40mmHg of pressure, a motor was used in conjunction with a stainless 
steel shaft key to align 6 separate cams, with spacers separating them, each exerting 40 
mmHg on each tissue sample. The cams were offset radially to ensure a balance of 
pressure on the motor. The circular profile of the cams was offset by 0.250’’ (measured 
distance to exert 40 mmHg by manometer). To ensure the rotation speed of 60rpm would 
be consistent, each piston stroke of the individual cams was timed separately. We also 
wanted to be able to retrieve individual samples at different time points (i.e. 1 week, 2 
weeks, etc.). For this reason we decided to use six separate pistons and we implemented 
valves to allow for individual retraction of sample holders. Through the PVC tubing, the 
samples were exposed to calcium in the SBP allowing for the uptake of calcium to occur. 
We also wanted the tissue samples to be at physiological temperature, which we 
controlled using a temperature-regulated shaker bath set to 37.5°C. 
 
Materials used for construction: 
 
All manufactured plastic components are made of Delrin (Acetal). 
All valves and fittings are made of Polyvinyl Choride (PVC). 
The clear tubing used is PVC. 
All metal components are 6061 aluminum. 
Springs, bearings and shaft connected to the motor are stainless steel. 
Emery paper is 100 grit. 
O-rings and seals are Buna Rubber. 
Reservoir is made of Acrylic plastic. 
 
Figures shown below: 
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Pressurized Flow System for Calcification Studies 
 
 
Individual Sample Holders used in Pressurized System 
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Appendix C: Calcium Reduction Testing Data 
 
Zero Pressure Calcification Reduction Test Data using AAS, ICP-MS, µCT(Groups A,B) 
 
 
 
 
 
Pressurized Calcification Reduction Test Data using AAS, ICP-MS, µCT (Groups A,B) 
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Calcium uptake in BP samples in Group A – Zero Pressure 
 
Time 
(days) 
AA 
(ppm) 
ICPS 
(ppm) 
µCT  
(ppm) 
7 31.5 ± 6.5 21 ± 2 29.7 ± 6.86 
14 136.7 ± 56.2 106.4 ± 61.8 175.3 ± 64.5 
21 705.7 ± 119.2 877.3 ± 80.4 709.2 ± 101.7 
28 1441.3 ± 317.6 1783.3 ± 384.2 1471.8 ± 262.5 
 
 
Calcium uptake in BP samples in Group B – Zero Pressure 
 
Time 
(days) 
AA 
(ppm) 
ICPS 
(ppm) 
µCT 
(ppm) 
7 12.7 ± 2.6 13.7 ± 2.1 13 ± 2.9 
14 42 ± 7.2 54.7 ± 10 53.3 ± 9.2 
21 331.5 ± 40.4 337.7 ± 69.3 330.5 ± 43.4 
28 611.7 ± 89.6 776 ± 120.4 618.8 ± 66.5 
 
 
Calcium uptake in BP samples in Group A – Pressurized 
 
Time 
(days) 
AA 
(ppm) 
ICPS 
(ppm) 
µCT  
(ppm) 
7 133.7 ± 56.3 86 ± 11 121.3 ± 17.4 
14 570 ± 86.5 416.7 ± 73.6 648.3 ± 81.2 
21 2676 ± 253.4 3520.3 ± 436.7 2682.5 ± 284.8 
28 5609.5 ± 406.3 6987.2 ± 341.78  5976.3 ± 332.4 
 
 
Calcium uptake in BP samples in Group B – Pressurized 
 
Time 
(days) 
AA 
(ppm) 
ICPS 
(ppm) 
µCT 
(ppm) 
7 49.2 ± 15.4 66.3 ± 13.9 62 ± 6.4 
14 175.3 ± 40.5 240 ± 65.1 218.3 ± 48.5 
21 1309 ± 178.7 1352.7 ± 129.8 1179.7 ± 197.2 
28 2428.7 ± 389.2 3151.2 ± 195.3 2368.5 ± 193.9 
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Calcium uptake in BP samples in Group C - Pressurized 
 
Time 
(days) 
AA 
(ppm) 
ICPS 
(ppm) 
µCT 
(ppm) 
7 91.8 ± 11.2 96.8 ± 15.4 94.3 ± 12.8 
14 336.3 ± 66.5 466.7 ± 69.2 343.8 ± 52.7 
21 1920.7 ± 293.6 2519.8 ± 357 2018 ± 114 
28 3937.8 ± 351.7 5082.2 ± 292.9 3892 ± 361.4 
 
 
Calcium uptake in BP samples in Group D - Pressurized 
 
Time 
(days) 
µCT  
(ppm) 
7 73.2 ± 9.06 
14 299.7 ± 47.12 
21 1655 ± 166.72 
28 2972.1 ± 301.97 
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Appendix D: Additional SEM Images of Calcium Sites on BP 
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Appendix E: Copyright Permissions 
Figure 2.3 
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Figure 2.4 
 
 
 
 
123 
 
 
 
 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
Curriculum Vitae 
 
Name:	  	   	   Asha	  Parekh	  	  	  
Post-­‐secondary	  	   Doctor	  of	  Philosophy	  (Candidate)	  
Education	  and	  	   Biomedical	  Engineering	  Graduate	  Program	  
Degrees:	  	   	   The	  University	  of	  Western	  Ontario	  	  London,	  Ontario,	  Canada	  2015	  PhD	  	  
Supervisor:	  Dr.	  Wankei	  Wan	  	  
Master	  of	  Engineering	  The	  University	  of	  Western	  Ontario	  London,	  Ontario,	  Canada	  2011	  MEng	  	  
Bachelor	  of	  Engineering	  Science	  The	  University	  of	  Western	  Ontario	  London,	  Ontario,	  Canada	  2007	  BESc	  	  	  
	  
Presentations:	   *presenter	  	  
	  
Oral	  Presentations	  
	  Parekh,	  A.*,	  Talman,	  E.,	  Wan,	  W.K.	  Improved	  Durability	  of	  Bovine	  
Pericardial	  Heart	  Valves.	  Canadian	  Society	  for	  Chemical	  Engineering	  Meeting,	  London,	  Ontario.	  (October	  2011)	  
	  Parekh,	  A.*,	  Talman,	  E.,	  Wan,	  W.K.	  Calcium	  Reduction	  in	  
Pericardium	  for	  Bioprosthetic	  Heart	  Valves.	  Canadian	  Biomaterials	  Society	  Meeting,	  Halifax,	  Nova	  Scotia.	  (June	  2014)	  	  
Poster	  Presentation	  
	  Parekh,	  A.*,	  Talman,	  E.,	  Umoh,	  J.,	  Wan,	  W.K.	  Reducing	  
Calcification	  of	  Bioprosthetic	  Heart	  Valves.	  London	  Health	  Research	  Day	  Conference,	  London,	  Ontario.	  (March	  2012)	  	  	  	  
	  
126 
 
Related	  Work	  	   Graduate	  Teaching	  Assistant	  
Experience:	  	   	   Advanced	  Biomaterials	  Engineering	  Biomedical	  Engineering	  Graduate	  Program	  and	  Department	  of	  Chemical	  and	  Biochemical	  Engineering	  	  The	  University	  of	  Western	  Ontario,	  London,	  Ontario	  2011-­‐2014	  	  	  Graduate	  Teaching	  Assistant	  
Chemical	  Engineering	  Project	  Chemical	  and	  Biochemical	  Engineering	  	  The	  University	  of	  Western	  Ontario,	  London,	  Ontario	  2011-­‐2015	  	  
	  
	  
Relevant	  Graduate	  	  Biomedical	  Engineering	  Graduate	  Program	  	  
Courses:	   	   The	  University	  of	  Western	  Ontario,	  London,	  Ontario,	  Canada	  
	  	   BME	  9513	  	   	   Medical	  Imaging	  BME	  9525	  	   	   Advanced	  Biomaterials	  Engineering	  BME	  9550	  	   Principles	  of	  Communication	  and	  Knowledge	  Translation	  for	  Biomedical	  Engineers	  	  BME	  9650	   Research	  and	  Knowledge	  Transition	  for	  Biomedical	  Engineers	  CBE	  9245	   Cellular	  Bioengineering	  VASCPROG	  9560	   Vascular	  Imaging	  	  VASCPROG	  9603	   Introduction	  to	  Biostatistics	  and	  Ethics	  for	  Biomedical	  Engineers	  	  	  	  	  	  
 
